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What we have done for ourselves alone dies with us; what we have done for others and the 
world remains and is immortal. 
– Albert Pike 
 
I hate quotations. Tell me what you know. 











POPULAR SCIENCE SUMMARY OF THE THESIS 
The largest leap in the evolution of our immune system occurred around 400 million years ago 
with the development of a new compartment known as the adaptive immune system. Instead 
of relying on inherited immune receptors passed down over generations, a new set of tools 
allowed the random generation of new immune receptors capable of binding almost any 
antigen, even those never encountered before. While the new system greatly improved our 
ability to quickly adapt to new pathogens, the random receptors also posed a new risk; some of 
the new receptors might target antigens in our own body. This new weapon to protect the body 
was the equivalent of a nuclear bomb in the evolutionary arms race between host and pathogen. 
Although instead of fearing mutual destruction from a nuclear war, we were, from this point 
forward, at risk of destroying our own body. Several control mechanisms developed to prevent 
the immune system turning against us. Despite this, investigators today have identified over 
100 different types of autoimmune diseases targeting almost every imaginable tissue, from 
head to toe. 
One of the most common autoimmune diseases is rheumatoid arthritis (RA) which affects 
nearly 1% of the world population, predominantly women. In RA the joints are attacked by the 
immune system causing joint inflammation and pain, this eventually leads to joint destruction 
if not treated. The most common biomarkers used to diagnose RA in the clinics are 
autoantibodies; the origin and function of these are however not known. 
The work presented in this thesis is an attempt at discovering the origin and function of different 
subclasses of autoantibodies. One of the subclasses are antibodies against type II collagen (CII), 
the major protein in the joint cartilage. These antibodies have previously been shown to be 
associated with the onset of RA, and cause arthritis when injected in animals. To better 
understand them, we have synthesized a library of CII peptides and used them to screen the 
serum of more than 4000 RA patients and 1500 healthy controls, confirming that several of 
them are associated with RA. 
If these antibodies could be identified in patients at an early stage, they may become the target 
for new treatment strategies. Depleting or neutralizing them could reduce symptoms such as 
antibody mediated pain or may even prevent RA from becoming established. 
There is currently no diagnostic test available for these antibodies, although the hope is that the 
new knowledge generated during this PhD project may help generate new biomarkers to aid in 




Ever since the evolution of an adaptive immune system capable of creating immune receptors 
that may recognize self-antigens, we have been at risk of autoimmunity. There are over 100 
different types of autoimmune diseases targeting almost every available tissue from head to 
toe, with joints and connective tissues being a common target. In addition to autoimmune 
diseases, infections and degenerative joint diseases can cause joint inflammation making 
differential diagnosis between them difficult. 
The most common autoimmune disease to afflict the joints is rheumatoid arthritis (RA), 
affecting nearly 1% of the world population, predominantly women. The etiology of RA is not 
known, although it involves interaction between multiple genes and environmental risk factors. 
It is characterized by chronic inflammation of the joints, which without successful treatment 
can lead to joint destruction. One of the hallmarks of RA is the presence of autoantibodies, 
often observed in serum several years before any symptoms of disease. The two classes of 
autoantibodies focused on today are rheumatoid factors (RF) and anti-citrullinated protein 
antibodies (ACPA), the latter being a highly specific biomarker for a large subset of RA-
patients. The ACPA have greatly aided in diagnosing RA in many patients. Yet their function 
and origin are still not known. Nevertheless, a subset of patients still lacks a specific biomarker. 
All studies in this thesis have autoantibodies in arthritis as a common theme, and four of them 
use a bead-based multiplex platform established during the PhD-project. In Study I, we 
explored the hypothesized link between periodontitis induced by the oral pathogen 
P.gingivalis, and its effect on arthritis progression and the production of ACPA. This study 
revealed a citrulline specific antibody response against P.gingivalis peptidyl arginine 
deiminase derived peptide, although the link to the arthritis development could not be 
confirmed. In Study II, we synthesized a library of triple helical peptides (THP) as a tool to 
characterize antibodies against type II collagen (CII). The peptides were tested in two cohorts 
of RA patients, as well as on monoclonal antibodies (mAb), and in collagen induced arthritis. 
The THPs were subsequently used in Study III to elucidate the specificity and function of 
antibodies against type XI collagen (CXI), revealing a shared epitope between CXI and CII in 
mice, rats and humans with arthritis. In addition, the THPs were also used in Study IV to 
explore the cross-reactivity of a joint-reactive mouse ACPA, demonstrating a molecular 
mechanism of how an ACPA can trigger arthritis. For Study V, the specificity of several human 
ACPA were dissected with a bead based multiplex assay and compared to polyclonal responses 
in two RA cohorts. Crystal structures of the ACPA revealed for the first time the structural 
basis of how human ACPA bind citrulline residues on different peptides. 
The data presented in this thesis provide further evidence that the major determinant of the 
arthritogenicity of antibodies lies in their ability to cross-react to joint proteins. Dissecting these 
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1.1 THE IMMUNE SYSTEM 
The role of the immune system is to protect the organism from diseases caused by foreign 
organisms and materials such as bacteria, viruses, fungi, and toxins. Even though we lack 
records from the earliest forms of life, it can be argued that the evolution of the immune system 
started with the origin of life. At a first glance the complexity of the human immune system 
involving a multitude of organs, cells and small molecules could be mistaken for an example 
of intelligent design. Yet as we examine our evolutionary ancestors, we can follow the gradual 
evolution of the immune system along the phylogenetic tree of life1. 
The degree of complexity of the immune system varies between organisms of different 
kingdoms and species, although it can be divided into different layers of protection. Surface 
barriers are the first line of defence to keep pathogens outside. They can be either mechanical, 
chemical, or biological. In humans they can be exemplified by the skin, low-pH environment 
in the stomach and commensal flora. 
1.2 INNATE IMMUNITY 
If the surface barriers are breached, the immediate response to the threat is orchestrated by the 
innate immune system, which is found in nearly all forms of life. Even bacteria have simple 
heritable defense mechanisms2, while all multicellular organisms appear to have a complex 
innate immune system3,4. The first function of the innate immune system is to identify the 
pathogens. This is done through pattern recognition receptors (PRRs)5, which are mainly 
expressed on cells of the innate immune system, such as macrophages, monocytes, dendritic 
cells, neutrophils, and mast cells. PRRs recognize molecules of two different classes: pathogen-
associated molecular patterns (PAMP), which are conserved molecular motifs expressed on 
pathogens and damage-associated molecular patterns (DAMP) released by host cells as a result 
of cell damage or cell death. Examples of PRRs include Toll-like receptors (TLR) capable of 
binding lipopolysaccharide (LPS) of Gram-negative bacteria6, and C-type lectin receptors 
(CLR) binding carbohydrate structures such as mannan on fungi cell walls7. The two other 
families of PRRs are Nod-like receptor (NLR) and RIG-I-like receptor (RLR)8. Once the PRRs 
of the immune system have been activated, cells release inflammatory mediators to recruit 
neutrophils and macrophages to the site of inflammation. Some of the effector mechanisms to 
kill the pathogens include phagocytosis, complement system and release of reactive oxygen 
species (ROS)9. 
1.3 ADAPTIVE IMMUNITY 
The final line of defense is the adaptive immune system. The principal components of our 
adaptive immune system are T and B lymphocytes, which through somatic recombination can 
assemble T and B cell receptors (TCR and BCR) specific for an immense range of antigens. In 
contrast to the innate immunity, an adaptive immunity response is not immediate. However, it 
is able to form immunological memory. These components are found in all jawed vertebrates 
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and marks a clear distinction in the evolution of the immune system, although jawless 
vertebrates carry a precursor to our adaptive immune system with other recombinatorial 
genes10. To put this into perspective, the earliest fossil records of jawed vertebrates are more 
than 400 million years old11. The random generation of TCRs and BCRs does however have 
the potential to generate receptors capable of recognizing self-antigens. To address this 
problem the development of T and B cells undergo a stringent process of selection to ensure 
self-tolerance; any cell not following the protocol may soon find itself on a path to 
autoimmunity12. 
1.4 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of 
peripheral joints causing cartilage destruction and bone erosion. The disease occurs in up to 
1% of the population, with women more often being affected than men. While the peripheral 
joints of the hands, feet and wrists are frequently affected, it is considered a systemic disease 
since it can also affect cardiovascular, skeletal, and respiratory systems. The cause of RA is not 
known, although the current dogma is that for a subset of patients, autoimmunity starts in a 
mucosal tissue in response to a chronic inflammation. This subset of RA patients is 
characterized by anti-citrullinated protein antibodies (ACPA) present in around 70% of 
patients13, measured in clinics using the commercial CCP2-test (cyclic citrullinated peptides 
kit, version 2). ACPA are a heterogenous subset of antibodies that can be detected in 1/5 of the 
patients already 10 years before onset of arthritis14. The other prominent autoantibody is 
rheumatoid factor (RF), often present together with ACPA15. The strongest genetic association 
to RA is with the HLA-DRB1 allele which together with environmental risk factors such as 
cigarette smoking show an epistatic interaction in the ACPA positive subset of RA patients16. 
There is currently no cure for RA, although the introduction of biological drugs targeting pro-
inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) has significantly reduced 
the burden of disease17. 
1.5 CLASSIFICATION OF RA 
In a disease such as rheumatoid arthritis in which the etiology is unknown and in which 
there is no available proof of the diagnosis, a broad description of the disease usually 
suffices for teaching and for diagnosis in individual cases. When such a method is used for 
classifying patients for study, however, there is little uniformity in the cases included in 
any series labelled rheumatoid arthritis. (Ropes MW et al, 1957)18 
One of the first attempts to classify RA was made by the American Rheumatism Association 
(today known as ACR, American College of Rheumatology) in 1957, in which patients needed 
to fulfill 5 out of 11 criteria to be classified as “definite” RA18. There were gradual 
modifications to the criteria over time, although it was not until a major overhaul leading to the 
1987 ACR revised classification criteria for RA19, that this classification became widespread. 
The revised 1987 guidelines were designed with the intention to be more specific creating a 




Table 1. The 1987 ACR revised classification criteria for RA. 
Criterion Description 
Morning stiffness Morning stiffness in and around the joints, lasting at least one hour 
before maximal improvement. 
Arthritis of three or 
more joint areas 
At least three joint areas (out of 14 possible areas; right or left PIP, 
MCP, wrist, elbow, knee, ankle, MTP joints) simultaneously have 
had soft tissue swelling or fluid (not bony overgrowth alone) as 
observed by a physician. 
Arthritis of hand 
joints 
At least one area swollen (as defined above) in a wrist, MCP, or PIP 
joint. 
Symmetric arthritis Simultaneous involvement of the same joint areas (as defined 
above) on both sides of the body (bilateral involvement of PIPs, 
MCPs, or MTPs, without absolute symmetry is acceptable). 
Rheumatoid 
nodules 
Subcutaneous nodules over bony prominences or extensor surfaces, 
or in juxta-articular regions as observed by a physician. 
Serum rheumatoid 
factor 
Demonstration of abnormal amounts of serum rheumatoid factor by 
any method for which the result has been positive in less than 5 
percent of normal control subjects. 
Radiographic 
changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand or wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in, or most 
marked adjacent to, the involved joints (osteoarthritis changes alone 
do not qualify). 
Note: For classification purposes, a patient has RA if at least four of these criteria are 
satisfied (the first four must have been present for at least six weeks). 
Table adapted from Arnett et. al, The American Rheumatism Association 1987 revised criteria for the classification 






Table 2. 2010 ACR/EULAR RA classification criteria 
Domain Category Point score 
A  Joint involvement (0–5 points)  
 
1 large joint  0 
2–10 large joints  1 
1–3 small joints (large joints not counted)  2 
4–10 small joints (large joints not counted)  3 
>10 joints including at least one small joint  5 
B  Serology (0–3 points)  
 
Negative RF and negative ACPA  0 
Low positive RF or low positive ACPA  2 
High positive RF or high positive ACPA  3 
C  Acute-phase reactants (0–1 point)  
 
Normal CRP and normal ESR  0 
Abnormal CRP or abnormal ESR  1 
D  Duration of symptoms 
 
<6 weeks  0 
≥6 weeks  1 
The points from each of domains A through D are added and the sum is considered to be the total 
score. A total score of ≥6 is needed to classify a patient as having definite RA.   
Table adapted from Aletaha D,  Neogi T,  Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an 
American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis 







1.6 GENETICS OF RA 
The heritability of RA is estimated to be around 60% based on twin studies, with a concordance 
rate among monozygotic twins at 15-30%20. The major histocompatibility complex (MHC) 
region contributes to more than half of the identified genetic heritability, with a set of HLA-
DRB1 alleles known as “shared epitope” having the largest contribution21. Shared epitope is a 
five amino acid motif (70-74) in the DRβ1 chain with either QKRAA, QRRAA or RRRAA 
shared between many DRB1 alleles. The most strongly associated allele in Caucasians is the 
DRB1*0401 which in addition also encodes risk associated amino acids in position 11, 71 and 
7422. Over 100 risk loci have been identified in RA23, although the disease association among 
the individual non-MHC genes is much weaker. Many of these are involved in regulation of 
the adaptive immune system (e.g., loci containing PTPN22, CD28 and CTLA4). Importantly, 
the MHC class II region and several non-MHC genes are associated with a specific 
autoantibody response to citrullinated proteins (anti-citrullinated protein antibodies, ACPA)24. 
While the heritability is the same for ACPA positive and negative RA, there is no predominant 
contribution of specific HLA-alleles in ACPA negative RA12. Another locus found in genetic 
studies of Japanese and Korean cohorts contains PADI4 which encodes the enzyme Peptidyl 
Arginine Deiminase 4 (PAD4) expressed in myeloid cells. PAD4 is proposed to be the PAD 
enzyme responsible for generating citrullinated autoantigens during chronic inflammation in 
mucosal tissues25. Surprisingly, this locus is associated to both ACPA positive and negative 
RA16,26. The total contribution of the risk genes identified so far cannot explain the estimated 
heritability in RA16, this gap is known as “the problem of missing heritability”, is seen in many 
complex diseases and is hypothesized to be caused by rare genetic variants, gene-gene 
interactions or gene-environment interactions not yet discovered27. Another explanation could 
be that the heritability from early twin studies is overestimated. However, a recent study on 
monozygotic twins shows that 15% have a substantial number of early developmental 
mutations specific to only one of them, implicating we may have underestimated the 
contribution of heritability in twin studies.28   
1.7 ENVIRONMENTAL RISK FACTORS 
1.7.1 Cigarette smoking 
The strongest environmental risk factor to date is cigarette smoking that has been demonstrated 
in a multitude of cohorts with RA patients29–33. The association with smoking also shows a 
possible epistatic effect together with several genetic risk factors highlighting the complex 
interactions between genes and environment in RA16,34,35. Adding to the complexity, cigarette 
smoke is a complex mixture of more than 7000 chemicals. One major component of cigarette 
smoke is nicotine which induces an anti-inflammatory effect through the cholinergic pathway 
and is shown to be protective in several autoimmune diseases and animal models of RA36,37. 
Nicotine is however also reported to induce formation of neutrophil extracellular traps (NETs) 
which release intracellular components that may act as autoantigens38. There are in addition 




Cigarette smoking is only one of the many aerosols that have been implicated in the etiology 
of RA as well as in several other autoimmune diseases; other examples are air pollution, silica 
dust, textile dust, pesticides, wood dust and mineral oils. Although they may act through 
different molecular pathways for the breach of self-tolerance, the common denominator is that 
these compounds may induce a chronic inflammation in the lung and in addition many of them 
show an epistatic effect together with cigarette smoking16,41. 
1.7.3 Periodontitis 
Periodontitis is an inflammation of the periodontium, which in its severe chronic form affects 
10% of the world population42. The association between oral health and inflammatory arthritis 
was described already by Hippocrates in ancient Greece who suggested pulling out teeth could 
cure arthritis. In addition to sharing pathophysiological similarities, they also have genetic 
(HLA-DRB1) and environmental (cigarette smoking) risk factors in common. 
1.7.4 Porphyromonas gingivalis 
One of the bacteria causing periodontitis (PD) is Porphyromonas gingivalis (P.gingivalis) found 
in around 80% of patients with periodontal disease43. It expresses a PAD enzyme (P.PAD) 
capable of citrullination44 not found in any other prokaryote to date. The proposed mechanism 
is that P.PAD will generate citrullinated epitopes of bacterial origin, which through a process 
of molecular mimicry will lead to cross-reactivity to citrullinated self-antigens (Figure 1)45. 
Ever since a hypothesis that citrullination by P.PAD could be a causative link between PD and 
RA46 was presented, the scientific community has put considerable effort into investigating this 
with mixed results45,47,48. While most reported experimental models show an increased severity 
in the group treated with P.gingivalis, one major problem in characterizing the ACPA response 
is the lack of a non-citrullinated control; the CCP2-kit used in most studies does not include 
one.  Moreover, other virulence factors in P.gingivalis such as LPS, collagenase and arginine 
gingipain B (RgpB) may also have a contribution to the link between PD and RA49. In 
summary, although epidemiological and experimental data support the role of P. gingivalis in 
the etiology of RA, there is yet no conclusive experimental evidence proving that citrullination 




Figure 1. Proposed mechanisms underlying the links between periodontal disease and the pathogenesis of 
rheumatoid arthritis. Figure from Potempa, et. al. Nat Rev Rheumatol 13, 606–620 (2017). Reprinted with 
permission from Nature. 
1.7.5 Aggregatibacter actinomycetemcomitans (Aa) 
While the scientific community studying the possible link between PD and RA has almost 
exclusively focused on P.gingivalis, a study from 2016 by Konig et. al.50 proposed the 
periodontal pathogen Aggregatibacter actinomycetemcomitans (Aa) as a candidate microbe 
responsible for the break of tolerance in RA. The proposed mechanism is that a pore-forming 
leukotoxin-A (LtxA) produced by Aa induces hypercitrullination in neutrophils, which through 
a process similar to NET formation exposes citrullinated self-antigens in the gingival tissue. 
Reports on experimental animal models exploring the link are so far scarce51, most certainly 
due to earlier reports that LtxA is specific for leukocytes of human or Old World primate 
origin52, although this narrow specificity is disputed53. The role of Aa in the development of 




1.7.6 Other infectious agents 
The idea that a pathogen may cause RA is not new, early theories suggested that the disease 
originated in pre-Columbian America and was spread to the Old World by the Europeans58. 
One of the most well studied pathogens is Epstein-Barr virus59–61 which has been detected in 
the synovial fluid in RA patients62. Subsequent theories include an unknown microbe spreading 
through blood transfusions63 and subclinical urinary tract infections by Proteus mirablis64. 
1.8 STRUCTURE OF COLLAGEN 
Collagens are the most abundant proteins; it is present in all animals with cells differentiated 
into tissues and makes up approximately 30% of the protein of mammals65. A total of 28 
distinct collagen proteins have been described, with the main fibril-forming collagens (type I, 
II, III, V and XI) accounting for 80-90% of all collagens in humans. The structural motif that 
defines the collagen proteins is their ability to form a triple helix made up by three polypeptide 
chains (Figure 2). The trimers are made up of either three identical polypeptide chains to form 
homotrimers (type II), or different chains to form heterotrimer (type I, XI)66.  
Figure 2. Structure of collagen. The amino acid sequence of collagen consists of Gly-Xaa-Yaa repeats, with Xaa 
and Yaa commonly occupied by proline and hydroxyproline. This unique sequence allows collagen to form an α 
helix secondary structure. Fibrillar collagen is a triple helix containing crosslinks formed through the action of 
lysyl oxidase. In vivo, these collagen fibrils form fibers with varying thickness and a D-banding pattern of 67 nm. 
Figure from Walimbe et.al., Best of Both Hydrogel Worlds: Harnessing Bioactivity and Tunability by 
Incorporating Glycosaminoglycans in Collagen Hydrogels.Bioengineering. 2020; 7(4):156. 
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1.8.1 Type II collagen (CII) 
CII is the major protein of the articular cartilage covering the joint surfaces and is made up of 
three identical α1(II) chains translated from the Col2a1 gene. In addition, it is also found in the 
cartilage of the nose, larynx, trachea and the vitreous. In similarity to other collagens, the 
sequence is highly conserved between species and the major B-cell epitopes are shared between 
humans, primates and rodents67.  
1.8.2 Type XI collagen (CXI) 
CXI is a heterotrimer composed of three distinct chains (α1(XI), α2(XI), α3(XI)). CXI forms 
heterotypic fibrils together with CII and type IX collagen (CIX) and is often colocalized with 
CII. The exact structure of the heterotypic fibrils is not determined, but it is hypothesized that 
CXI constitutes the inner core of the fibrils and therefore is less exposed (Figure 3). The α3(XI) 
is expressed by the Col2a1. As a result, it is identical to the α1(II) chain in CII apart from a 
higher degree of hydroxylation and glycosylation68. 
 
Figure 3. Three-dimensional model of the type II/IX/XI heterotypic fibril of developing cartilage matrix. 
Reprinted from Methods, 45/1, Eyre et. al. Advances in collagen cross-link analysis, 65-74., Copyright (2008), 
with permission from Elsevier 
1.9 ANIMAL MODELS 
The most commonly used animal for medical research is the mouse, and advances in recent 
decades to create genetically modified mice has made it into the model organism of choice for 
immunological studies69. Our latest common ancestor with the mouse is estimated at around 
65 million years ago and our immune systems have since evolved not only to different 
ecological niches, but also different body size and life span. Some of the major differences that 
have emerged between the humans and mice immune system include the balance between 
neutrophils and lymphocytes in peripheral blood, Toll receptors, Immunoglobulin subsets, Fc 
receptors and regulation and development of different B- and T-cell subsets70. Despite the 
lengthy period on diverging evolutionary paths using the mouse and other animals as a model 
organism for the immune system has been instrumental for our current knowledge71 and 
alternatives to animal models to study complex diseases are limited72. 
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1.9.1 Collagen induced arthritis (CIA) 
The current gold standard for preclinical experiments in arthritis is collagen induced arthritis 
(CIA) where CII is emulsified in complete Freund’s adjuvant73. Similar to RA, a major genetic 
risk factor for CIA is the MHC haplotype requiring a CII permissive MHC such as H-2r or H-
2q74. CIA can also induce arthritis in genetically susceptible rats and several species of 
monkeys, revealing that the major B-cell epitopes are conserved between species75. The disease 
development is dependent on both T and B-cells, leading to the production of anti-CII 
antibodies which are the major effector mechanism for disease induction. Finally, it was an 
important tool in development and testing of several biologically based therapeutics, such as 
IL-176, IL-677 anti-TNF-α78. 
1.9.2 Collagen type XI induced arthritis (CXIIA) 
A variant of the traditional CIA model is to substitute CII with CXI in the experimental 
protocol79. CXI forms a heterotrimer from three different chains (α1(XI), α2(XI), α3(XI)), one 
of which (α3) is shared with CII. As a result, a subset of anti-CXI antibodies can cross-react to 
CII80. Arthritis induced with homologous CXI leads to a more pronounced chronic relapsing 
arthritis compared to CIA81, displaying increased titers of anti-CXI antibodies during the 
chronic phase. The model is also MHC-dependent, albeit in rats, the associated MHC 
haplotypes differs between CIA and CXIIA 82. 
1.9.3 Collagen antibody induced arthritis (CAIA) 
The antibodies induced in CIA can be isolated and used to transfer disease in a model called 
collagen antibody induced arthritis (CAIA)83. Importantly, the dominant B-cell epitopes in CII 
are conserved between species67,84 and antibodies against different epitopes have been shown 
to be either pathogenic or protective85, yet all tested anti-collagen antibodies induce pain86. The 
standard CAIA cocktail uses 4 mAbs specific for C1, J1, U1 and the D3 epitope and is boosted 
with LPS87. The CAIA model is B- and T-cell independent and does not involve the priming 
phase in contrast to other models such as CIA. Consequently, it is used to study the disease 
onset phase and mechanisms for antibody mediated inflammation.  
1.9.4 Pristane induced arthritis (PIA) 
Arthritis can also be induced in rats through the immunization of different mineral oils88, 
pristane induced arthritis (PIA) is the most studied model due to high incidence (99,6%) and 
excellent reproducibility89. PIA has a quick onset starting around 10 days with a peak at around 
20 days. Thereafter, the inflammation steadily decreases before the start of a chronic relapsing 
disease with new inflammation. Isolated CD4+ T-cells can transfer the disease90, regulated by 
CLRs91. PIA induces the production of both RF, anti-CII92 and anti-CXI antibodies93. However, 
antibodies are not known to play a major role in the pathogenesis of PIA94. Interestingly, 
pristane induces chronic relapsing arthritis only in susceptible rat strains. In contrast, mice 
immunized with pristane display phenotypically different symptoms and instead develop a 
systemic lupus erythematosus (SLE) like disease in susceptible strains95. 
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1.9.5 Other experimental arthritis models 
In addition to collagens, the immunization of other cartilage associated proteins such as 
cartilage oligomeric matrix protein (COMP)96 and aggrecan97 can induce arthritis. The 
ubiquitous protein glucose-6-phospho-isomerase (GPI) can also induce arthritis upon 
immunization with an adjuvant98. The unlikely autoantigen was discovered in the K/BxN 
model as a result of transgenic T-cells specific for GPI, leading to the production of anti-GPI 
antibodies precipitating on the cartilage surface99 due to an interaction with proteoglycans100. 
These antibodies induce arthritis in the K/BxN serum transfer model through similar molecular 
mechanisms as CAIA101. Another similarity between GPI and CII as autoantigens is that 
arthritis induction through protein immunization is MHC dependent with an association to the 
H-2q haplotype98. 
Many other proteins have also been implicated as autoantigens in RA due to the cross-reactivity 
of ACPA including vimentin, fibrinogen, filaggrin, α-enolase and histones. There have been 
attempts to use these proteins to establish new arthritis models102, yet it is debated if any of 
them can induce experimental arthritis in a reproducible fashion103. The absence of data from 
experimental animal models does not exclude them as potential autoantigens. None of the 
animal models captures the full complexity of RA, instead each of them is an attempt to explain 
a limited phase or pathway of the disease.  
1.10 AUTOANTIBODIES IN RA 
1.10.1 Rheumatoid Factors (RF) 
Rheumatoid Factors (RF) are antibodies binding the Fc region of immunoglobulin G (IgG). 
They were identified in patients with RA more than 70 years ago104. The name RF was given 
due to the association with RA, although they are present both in other rheumatic diseases and 
non-rheumatic conditions, as well as in healthy individuals, especially the elderly105. The high 
prevalence of low-affinity RF during many infections points towards a key role in host 
defense106 prior to the induction of the high affinity RF observed in autoimmune disorders. The 
reported frequency in RA is between 60-90% and has a specificity of 85%. RF was the only 
autoantibody to be included in the 1987 ACR RA classification criteria, and since the 
introduction of standardized test for ACPA it is now interpreted together with ACPA status in 
clinical settings as exemplified in 2010 ACR/EULAR classification criteria for RA107. The 
presence of RF is correlated with a more erosive disease and studies exploring the interaction 
between RF and ACPA show a significant additive effect in the double positive subset 
(RF+/ACPA+) of patients108,109.  
1.10.2 Anti-citrullinated proteins antibodies (ACPA) 
The first observation of RA-specific antibodies was reported in 1964 and were named 
Antiperinuclear Factor (APK)110. It was followed by antikeratin antibodies (AKA)111 which 
were shown to bind the protein filaggrin112. Monoclonal antibodies against filaggrin showed 
that APK and AKA were in fact the same RA-specific antibody113. Despite the high specificity 
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for RA, the inconvenient testing method required hindered their use as a serological marker for 
clinical use. It was not until the discovery that citrulline was the antigenic target114 that 
standardized assays could be developed and ACPAs were later included in the 2010 
ACR/EULAR classification criteria for RA107. The standard assay used for detection of ACPA 
is the CCP2 ELISA test which contains a set of undisclosed synthetic cyclic citrullinated 
peptides with a reported sensitivity of over 70% and specificity above 98%115. In addition, there 
are several reports that the standard CCP2 assay doesn’t capture all ACPA, up to 20% of the 
CCP2 negative patients have antibodies binding other citrullinated antigens116. Even though 
ACPA have a high specificity for RA compared to RF105, they are also present in 1-2% of the 
general population without RA117. During a 3-year follow up of non-RA ACPA positive 
individuals in the Swedish twin registry only 8,5% developed RA, indicating that a positive 
ACPA status defined by the CCP2-kit has a limited predictive value for the onset of RA in the 
general healthy population118. For this reason, ACPA are currently only used as a biomarker 
for individuals which have symptoms of RA or other joint-related diseases.  
1.10.3 Anti-modified protein antibodies (AMPA) 
In recent years, antibodies binding other posttranslational modifications (PTMs) such as 
homocitrulline and acetylation have also been found119,120. There has been a controversy if 
these antibodies are in fact a distinct class of autoantibodies in RA121. A recent report studying 
BCR sequences from B-cells using citrullinated or acetylated antigens revealed that most mAbs 
were highly cross-reactive between multiple PTMs120. The high cross-reactivity of antibodies 
between different PTMs has led to the proposed model that the term ACPA should be replaced 
by AMPA: anti-modified protein antibody. 
1.10.4 Anti-CII antibodies 
The first report of collagen as a candidate autoantigen RA was made by Steffen in 1970122, 
although the initial studies in the field did not make clear distinction between different types of 
collagen making comparisons between studies confusing. The turning point came with the 
establishment of an experimental arthritis model comparing different types of collagen, 
identifying type II collagen (CII) as the major candidate123. While the link to the pathogenesis 
has been difficult to prove experimentally for other autoantibodies in RA, the arthritogenicity 
of anti-CII antibodies has been thoroughly investigated in experimental arthritis models such 
as CIA and CAIA67,73,83,85,124,125. In RA, anti-CII antibodies are associated with the acute onset 
and early stages of disease126,127. The prevalence of anti-CII antibodies in RA has yielded 
estimates between 3-88%128–130, highlighting the need for a standardized testing protocol with 
defined reagents. Despite a clear link to the pathogenesis of RA, the detection of anti-CII 




1.11 THE PATHOGENICITY OF AUTOANTIBODIES 
Epidemiological studies show that seropositive RA patients, in particular the double positive 
RF+/ACPA+ subset, have a more severe disease outcome108,109. One proposed mechanistic link 
for the additive effect is that RF forms immune complexes with ACPA which stimulate the 
release of pro-inflammatory cytokines from macrophages to stimulate osteoclasts109. There are 
reports indicating that ACPA in healthy individuals correlate with bone loss before clinical 
onset, but the specificity of ACPAs is not known131. Since the citrullinated cyclic peptides used 
in commercial kits are undisclosed and may not be expressed in vivo, one approach to find the 
mechanistic link has been to study fine specificities of ACPA against citrullinated peptides 
from different putative autoantigens. The proteins that have been studied most extensively 
include fibrinogen, vimentin, α-enolase, filaggrin and CII, although with mixed results14,132–135. 
Several animal models have reported arthritogenicity of ACPA, although low antibody titers 
and lack of appropriate non-citrullinated control in most studies make the causative link 
inconclusive136–138. The production of ACPA is however not the feature of any of the 
established animal models for arthritis, and B-cells recognizing citrulline are negatively 
selected in the mouse139. There are also reports of purified polyclonal and monoclonal human 
ACPA with arthritogenic properties140–142.  
Finally, the ACPA isolated from mice have been shown to induce (ACC1) or enhance (ACC4) 
arthritis143,144. A recent publication of the first crystal structure of a human ACPA revealed how 
it was able to cross-react between different citrullinated peptides145. In contrast, the crystal 
structures of the two mouse ACPA revealed how they could either cross-react to native CII 
(ACC1) or be specific to one citrullinated epitope on CII (ACC4)143,144. The different cross-
reactivity of ACPA in relation to antibodies known to induce arthritis in animal 
models96,99,124,143, led to proposing a model of three different classes of ACPA where their 
functional roles are determined by their specificity (Figure 4). In this proposed model the 
antibodies which cross-react with joint proteins are arthritogenic and have an important role in 
the onset of arthritis, while the ACPAs that are widely cross-reactive to citrullinated peptides 
may have a role in the pathogenesis after the inflammation in the joint has been established. 




Figure 4. Examples of different types of ACPAs and joint-reactive autoantibodies in RA. Illustration of the 
binding of antigen by different types of autoantibodies in rheumatoid arthritis (RA), each exemplified by a 
crystallized antibody–peptide complex. Figure from Ge et. al. Nat Rev Rheumatol 15, 503–508 (2019). 
Reprinted with permission from Nature. 
1.12 PATHOGENESIS OF RA 
To summarize the etiology of RA, a model for disease development in RA divides it into three 
separate stages; priming, disease onset and chronic joint inflammation147 (Figure 5). 
At stage one, autoimmunity emerges from exposure to environmental risk factors such as 
cigarette smoke and pathogens in genetically pre-disposed individuals. While epidemiological 
studies show a strong epistatic effect between genetic and environmental risk factors in the 
development of RA, a study of 12,590 twins suggests that induction of ACPA in the general 
population correlates more strongly with environmental exposures rather than genetic risk 
factors117. The exact location is not known, although it is postulated to occur in the mucosal 
membranes such as periodontium, gut, or the lung tissue148. The initial stage is characterized 
by the production of RF and ACPA which can be detected in the serum several years before 
the diagnosis in a subset of patients14,149. The antibody profile of these autoantibodies during 
the pre-symptomatic phase shows low titers and autoantibodies shown to induce arthritis are 
not present.  
In the second stage around the onset of RA, the autoantibody profile changes drastically with 
a rise in titer, affinity, epitope spreading and with antibodies targeting joint proteins14. The joint 
protein that has been most extensively studied is CII, which is the major protein in the joint 
cartilage and antibodies against CII in RA are associated with an early inflammatory and 
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destructive phenotype127. Why only a minority of individuals that are ACPA positive develop 
arthritis is not known; the current dogma around this switch to joint reactivity argues for a 
genetical predisposition, most notably HLA-DRB1 alleles and other T-cell activating genes 
such as PTPN22.  
The third and final stage is chronic inflammation of the joints. This phase leads to tissue 
destruction and remodeling; the patients that have reached this stage represent the vast majority 
seen by clinicians. This is also the focus for the current therapies. The most efficient treatments 
at this stage target cytokines produced by macrophages such as TNF-α and interleukin-6 (IL-
6), although we currently lack biomarkers for predicting which patients will respond to the 
treatment. For seropositive patients, therapies targeting T and B-cells have also shown to be 
efficient, indicating that adaptive immunity also plays a role in chronic phase for this subset of 
patients150. While anti-B-cell therapy works in a subset of RA patients, the functional role of 
autoantibodies in the chronic phase is still not clarified. Once the disease is established, new 
cartilage proteins/epitopes normally hidden to the immune system may be exposed. One 
candidate autoantigen to illustrate this established phase is type XI collagen which is postulated 
to be located inside the collagen fibers, and to which antibodies are seen at a late stage of 
disease in experimental arthritis151. The exposure of neoantigens and cross-reactivity between 
these and other joint proteins152 could further perpetuate the disease and have an impact on long 
term remission. 
 
Figure 5. The three stages of the development of RA. Figure from Ge et. al. Nat Rev Rheumatol 15, 503–508 




The original goal of this PhD project was to investigate environmental risk factors of RA in 
animal models of arthritis, with a focus on the origin and function of ACPA. Out of the 5 
projects included in the original research plan, two of them are published in this thesis (Study 
I and Study IV). The remaining original projects were not included in the thesis due to 
limitations in reagents, genetically susceptible mice strains and access to facilities. Instead, the 
PhD project took a new turn and led to establishing a platform for studying joint-reactive 
autoantibodies and using it to analyze animal models of arthritis, monoclonal antibodies and 
human patient cohorts with inflammatory joint diseases (Study II-V). 
Study I examined the age-old theory of a link between periodontitis and arthritis. Our 
investigation focused on the hypothesis by Rosenstein et. al. that the immune response to the 
oral pathogen P.gingivalis may be involved in the etiology of RA46. While there are several 
mechanisms by which a P.gingivalis induced periodontitis can influence arthritis development, 
the cornerstone in this theory is that P.PAD enzyme could induce autoimmunity in RA through 
molecular mimicry of citrullinated antigens.  
In Study II, our goal was to address a major bottleneck for characterizing CII as an autoantigen 
in RA: a library of high-quality triple helical peptides. Once established, the library would be 
instrumental for investigating the role of anti-CII as biomarkers and pathogenic factors in 
arthritis. 
For Study III the aim was to examine CXI as an autoantigen in arthritis by immunization and 
isolating anti-CXI clones to characterize their function, specificity and arthritogenicity. 
An ACPA-clone of mouse origin that binds both cyclic citrullinated peptides and non-
citrullinated CII-peptides has been an enigma since its first report143. In Study IV the quest was 
to solve this puzzle and determine the structural basis for the cross-reactivity and determine its 
function. 
Finally, in Study V, we searched to further explore the cross-reactivity of ACPA with a series 





3 METHODOLOGICAL CONSIDERATIONS 
This section provides a summary of selected key methods used in the projects included in this 
thesis. More detailed methodology can be found in the original manuscripts of Study I-V.  
3.1 PATIENT MATERIAL 
3.1.1 TIRA-2 
In Study II, IV and V, we analyzed the antibody reactivities in serum samples from the 
prospective cohort second Swedish Early Intervention in RA Trial (TIRA-2)31. Early RA 
patients with symptom duration of at least 6 weeks and up to 12 months were recruited from 6 
rheumatology units in mid- or southeast Sweden between 2006-2009. Most patients (84%) 
fulfilled the 1987 criteria from ACR19. Two smaller groups were recruited, either having 
morning stiffness with a duration of >60 minutes, symmetric arthritis, and small‐joint 
engagement of the hands or feet (5% of patients), or ≥1 joint with palpable synovitis and anti‐
CCP positive (11% of patients). At the time of first serum sampling, all patients were naïve for 
Disease-modifying antirheumatic drugs. 
3.1.2 BARFOT 
In Study II, we analyzed antibody reactivities in serum samples from the Better Anti-
Rheumatic PharmacOTherapy (BARFOT) cohort153. This is an observational prospective 
multicenter study of patients with early RA that were recruited between 1992-2006. To be 
included in the study, participants had to fulfill the revised 1987 criteria from ACR19 and have 
a disease duration of up to 12 months. 
3.1.3 EIRA-1 
In Study III and V, we analyzed antibody reactivities in serum samples of RA patients and 
controls from the Epidemiological Investigation of RA (EIRA-1) cohort32. This population-
based case-control study started in 1996 and diagnosed RA patients using the revised 1987-
criteria from ACR154. Patients between 18-70 years old were recruited within 12 months from 
the first symptoms of arthritis from rheumatology clinics in southern and central Sweden. 
Controls for the study were recruited at random from the national population registry, matched 
for gender, age and residential area. The patients included in EIRA-1 partially overlaps with 
the previously described BARFOT cohort. 
3.1.4 Population controls 
For both TIRA-2 and BARFOT, no case controls were recruited as part of the original study 
design. Instead, controls recruited for other patient cohorts were used. 
3.1.4.1 WINGA 
In Study IV and V, controls recruited to be used in the Western Region Initiative to Gather 
Information on Atherosclerosis cohort (WINGA) were used. In addition, controls diagnosed 
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with a rheumatic disease in the patient registry were excluded. A limitation with these controls 
were that they were recruited to match atherosclerosis patients which have a different gender 
and age distribution compared to RA. 
3.1.4.2 Malmö Diet and Cancer Study 
In Study II, age and gender matched controls for BARFOT and TIRA2 were obtained from 
population controls used in the Malmö Diet and Cancer Study. Individuals diagnosed with a 
rheumatic disease were excluded.  
3.2 EXPERIMENTAL ANIMALS 
In Study I and III, rats from the inbred DA strain were included. For Study II, III and IV mice 
strains susceptible to arthritis carrying either the H2q or H2r MHC-haplotype were used. All 
animals were bred and kept under specific pathogen free conditions (FELASA II) at the animal 
facility of Medical Inflammation Research. Water and pellets were provided ad libitum and 
they were housed in individually ventilated cages. 
3.3 LIGATURE-INDUCED EXPERIMENTAL PERIODONTITIS 
For the induction of periodontitis in Study I, silk ligatures were tied around the second upper 
molar on both sides under anesthesia155. The periodontitis was evaluated every 10 days by a 
trained dentist, and after each examination swabs of the oral pathogens P.gingivalis and 
F.nucleatum were applied to facilitate the development of periodontitis. 
3.4 EXPERIMENTAL ARTHRITIS 
3.4.1 Pristane Induced Arthritis (PIA) 
The PIA model used in Study I and III was induced by a single intradermal injection of 100 
μl pristane (2,6,10,14-tetramethylpentadecane) at the dorsal side of the tail base. The disease 
progression was measured by weighing and clinical scoring on a 60-point scale156. 
3.4.2 Collagen Induced Arthritis (CIA) 
In Study II and III the CIA model was used. Arthritis was induced by an intradermal injection 
of emulsion made from rat CII and complete Freund’s adjuvant (CFA). At day 35, a booster 
injection with CII and incomplete Freund’s adjuvant was injected intradermally. The disease 
progression was measured by clinical scoring on a 60-point scale. In addition, for Study III a 
modified protocol substituting CII with CXI was also used. 
3.4.3 Collagen Antibody Induced Arthritis (CAIA) 
To evaluate the arthritogenicity of monoclonal antibodies, the CAIA model was used in Study 
III and IV. The monoclonal antibodies were injected intravenously, either alone or as a cocktail 
together with other monoclonal anti-CII antibodies. The mice were boosted with an 
intraperitoneal injection of LPS on day 5. Clinical scoring was done on a 60-point scale.  
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3.4.4 Bead-based multiplex assay 
In Study II-V, we analyzed antibody responses using the Luminex platform. For Study II,  a 
platform established at Medical Inflammation research with a Bio-plex 200 was used. For 
Study IV and V, a platform established at the Plasma Profiling division at Sci-Life was used. 
For Study III, both plaforms were used. Magnetic beads with unique dyes were first coated 
with NeutrAvidin, thereafter coupled with biotinylated peptides. The process was optimized 
testing different concentrations of NeutrAvidin and biotinylates peptides. Next, human or 
rodent samples were diluted and pre-incubated in a blocking buffer for 1 h at RT on a shaker. 
Different serum concentrations and blocking buffers were evaluated during optimization. The 
most important modification from the original protocol was the addition of NeutrAvidin to 
reduce unspecific binding. Thereafter, the beads with different peptides were mixed with the 
serum samples and incubated for 75 minutes. beads were washed on a plate washer and then 
resuspended in a solution containing the secondary anti-human, anti-rat or anti-mouse IgG Fcγ-
PE. After 40 min of incubation, the beads were washed and the fluorescence intensity was 
measured. The median fluorescence intensity (MFI) was used to quantify the interactions of 
the antibody with the given peptides. For the comparison of responses to peptides in human 
serum samples in Study II, III and V, the ratio value (fold change), calculated by dividing the 
MFI value for the peptide of interest by the MFI value of either the median value of cyclic 
controls peptides or the THP control peptide (described in Study II), was used. In Study IV 
the THP control had not yet been synthesized. 
3.5 STATISTICAL METHODS 
To compare numerical data between two independent groups where normal distribution could 
be assumed, analysis was made with the student’s t test (two-tailed) (Study I). In contrast, the 
non-parametric method Mann-Whitney U test (also called Wilcoxon rank-sum test) was used 
for independent group comparisons of numerical data where normal distribution could not be 
assumed (Study I-V). To compare categorial data of two independent groups, Fischer’s Exact 
test was applied (Study II-IV). Pearson correlation test was used for calculating correlations 
for independent numerical variables (Study III). Statistical analyses were performed with IBM 
SPSS Statistics 21.0 (Study I), GraphPad Prism v8.0.1 Software (Study II-III) or R software 
using several packages (Study IV-V). P-values <0.05 were considered statistically significant. 
3.6 ETHICAL CONSIDERATIONS 
All studies in the thesis have been approved by local ethical committees.  
That being said, scientists must reflect on all aspects of their research, including ethical. For 
this PhD project, the animal experiments are obviously the focal point. 
The first question is why? RA is a severe autoimmune disease affecting up to 1% of the 
population, and there is no cure. Looking back at history, the use of animal research has been 
instrumental in development and testing of several biologically based therapeutics targeting 
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pro-inflammatory cytokines (IL-176, IL-677, anti-TNF-α78). The introduction of these has 
revolutionized the care and treatment of RA patients.  
The downside of performing animal experiments is of course the suffering caused. Comparing 
the suffering caused by RA to the suffering caused in arthritis experiments is no easy task, 
although an attempt to quantify would probably be in favor for performing experiments. 
Unfortunately, for complex disease such as RA, it’s not possible to replace animal experiments 
with cells, “organs-on-a-chip” or in silico studies. 
Although if rodents have the similar capacity to suffer and feel joy, why don't they have 
unalienable rights just like us? Judging by how the emancipation of our own species has 
evolved over time and only recently come to include all members, future generations will 




4 PRESENT INVESTIGATIONS 
4.1 STUDY I: EFFECTS BY PERIODONTITIS ON PRISTANE-INDUCED 
ARTHRITIS IN RATS 
In Study I we explored the role the oral pathogen P.gingivalis in the pathogenesis of RA. The 
proposed link between the two46 was the result of two independent observations reported within 
a year of each other; the identification of ACPA as a biomarker in RA114 and the P.PAD enzyme 
in P.gingivalis44. Since the first report of cross-reactivity between citrullinated human alpha-
enolase (CEP-1) and bacterial enolase157 in RA, the scientific community has yielded numerous 
(Figure 6) epidemiological158,159 and experimental160,161 evidence in support of the link47. 
 
Figure 6 Number publications per year with the keywords “gingivalis” and “rheumatoid arthritis” in 
Pubmed between 1990-2020. A: Identification of ACPA as a biomarker in RA. B: Identification of PAD enzyme 
in P.gingivalis. C: Proposed link between P.gingivalis and RA. D: Report of antibody cross-reactivity between 
citrullinated alpha-enolase and bacterial enolase in serum of RA patients. 
The experimental periodontitis model with ligatures and pathogens showed early clinical signs 
in most rats already 3 weeks into the experiment; at week 6, severe periodontitis was 
established in all rats. The periodontitis measured by a tooth mobility score, reached a plateau 
after 8 weeks. The alveolar bone level was measured through micro-CT, confirming a 
significant bone loss in the periodontitis group after 15 weeks. In contrast, the group with only 
arthritis had no significant alveolar bone loss or tooth mobility score compared to healthy 
controls. Arthritis observed in rats after pristane immunization at week 8 was comparable 
across all groups. No significant difference was observed in the acute phase protein α-1-AGP 
or the 20-plex cytokine test between the experimental groups.  
Antibodies against the RgpB were found in 8 of 9 rats with periodontitis. In contrast, no 
response to RgpB was found in rats without periodontitis (Figure 7a). To characterize a 
citrulline specific antibody response, the citrullinated peptides CPP3 and CEP-1 with their 
corresponding controls RPP3 and REP-1 were examined revealing a significant increase in the 
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concentration of anti-CPP3 antibodies in the periodontitis group (Figure 7b). No difference was 
observed between the groups in the antibody titers against RPP3, CEP-1 or REP-1. 
Figure 7 Effect of pre-existing periodontitis on the 
antibody response to RgpB and PPAD. Plasma RgpB, 
CPP3 and RPP3 levels. Mean plasma concentrations 
(AU/ml ± SE) of antibodies against (a) RgpB, (b) 
CPP3 and RPP3 in arthritis rats with and without 
periodontitis and healthy control animals at endpoint 
of the experimental period of 15 weeks. *P<0.05 was 
considered statistically significant. PA rats with 
experimental periodontitis and PIA (n=9), A rats with 
PIA without periodontitis (n=12), Healthy control rats 
without induced arthritis or periodontitis (n=4), RgpB 
arginine gingipain B, CPP3 citrullinated peptide 
derived from PPAD, RPP3 arginine-containing 






Our investigation combined two established animal models for periodontitis and arthritis: 
ligature-induced periodontitis and PIA. To promote the progression of periodontitis, swabs of 
P.gingivalis and F.nucleatum were applied after each oral examination. The combination was 
chosen based on earlier reports demonstrating that F.nucleatum can promote the colonization 
of anaerobic bacteria such a P.gingivalis162 and display an epistatic effect in the induction of 
bone loss in experimental periodontitis163. Chronic periodontitis evaluated by a tooth mobility 
score was established before the induction of arthritis at week 8. The inability to reproduce 
previous findings, that P.gingivalis promotes the development of arthritis in experimental 
models160,161, may be explained by the experimental models chosen. For instance, CIA is the 
most frequently used animal model of arthritis where anti-CII antibodies are an important 
effector mechanism164. In contrast, the PIA model is a T-cell driven model. While PIA does 
induce both RF165, anti-CII92 and anti-CXI93 antibodies, their role in the pathogenesis has not 
been clarified. Another limitation of using PIA in DA rats is the very high severity of joint 
inflammation which could mask any potential additive effect of periodontitis. The choice of 
experimental periodontitis model could also be a contributing factor explaining conflicting 
results. However, our study spanning over 15 weeks allowed evaluation of both early and 
chronic stages in both periodontal and arthritic disease. At the time of publication, this was the 
longest animal study exploring the relationship between periodontitis and arthritis. 
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While no animal study can ever capture the full complexity of a human disease, we might need 
to ask ourselves if all animal experiments are equally informative? For instance, one may 
question the scientific relevance of using a method described as “Chronic inflammatory lesions 
were induced by the implantation of polyurethane sponges impregnated with heat-killed 
Porphyromonas gingivalis into the backs of DA rats.”160 to explore a link between periodontitis 
and RA in humans. The correlation found in this particular study rather implies any chronic 
inflammation in the body may exacerbate disease severity in experimental arthritis models. 
The analysis of ACPA production revealed a CPP3 specific response in the group with 
periodontitis while no difference was observed in the response towards CEP-1 or their 
corresponding control peptides. This is the first report of antibodies against a citrullinated 
P.PAD peptide in an experimental animal model. While we could not detect any other ACPA 
reactivity, an immune response towards a citrullinated foreign antigen would be the first step 
in a proposed mechanism of molecular mimicry between P.PAD and an unknown self-antigen. 
A limitation in the experimental setup is the duration of the priming phase of disease which in 
RA is thought to span over years rather than months. A longer study period may eventually 
have yielded epitope spreading toward other citrullinated antigens. Numerous animal studies 
have in contrast to our results reported more general ACPA-reactivity based to the CCP2 kit166. 
However, the CCP2-kit does not provide a negative control and is subsequently of limited value 
to determine if the response is citrulline specific. Response to CPP3 has also been found in 
elevated levels in RA, both in pre-symptomatic samples and in established-RA167. However, 
these findings were not reproduced in a smaller cohort168. There is also a report that P.PAD 
cannot auto-citrullinate169, implying that citrullinated P.PAD and any peptides derived from it 
(CPP3) are not unique antigens providing the mechanistic link between P.gingivalis and RA. 
However, this study is disputed170 and quest to find the proof of a mechanistic link continues. 
In summary, periodontitis induced by P.gingivalis did not affect the development or disease 
severity of pristane-induced arthritis in DA rats. However, in rats with periodontitis we were 
able to detect a citrulline specific response towards a P.PAD derived peptide. 
4.2 STUDY II: SYNTHESIS OF AN ARRAY OF TRIPLE-HELICAL PEPTIDES 
FROM TYPE II COLLAGEN FOR MULTIPLEX ANALYSIS OF 
AUTOANTIBODIES IN RHEUMATOID ARTHRITIS 
In Study II we set out to establish a library of triple helical peptides of the major B-cell epitopes 
in CII to use as biomarkers for screening anti-CII antibodies. Collagen has been a proposed 
autoantigen in RA for over 50 years122. Since then, the pathogenic properties of anti-CII 
antibodies have been extensively studied in experimental animal models171 and their potential 
role in the onset of RA has been confirmed in several studies126,127. However, the use of anti-
CII antibodies as a biomarker has never been established for clinical use. In contrast, RF and 
ACPA are included in the 2010 ACR/EULAR classification criteria for RA107. The rapid 
introduction of ACPA as a classification criterion was possibly due to the commercial 
availability of standardized assay13. At the same time, there is no standardized diagnostic assay 
for anti-CII antibodies, illustrated by the reported prevalence in RA varying between 3-88%128–
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130. In addition, different subsets of anti-CII antibodies may have different function and 
diagnostic value depending on their epitope specificity. For instance, while mAbs directed 
against the C1, U1, J1 and D3 epitopes induce arthritis87, the F4 epitope has been reported to 
be protective172 and is not associated with RA173. The binding of anti-CII antibodies is 
conformation dependent, requiring a triple helical structure174. To dissect the different subsets 
of anti-CII antibodies, triple helical peptides with different inserts are therefore needed which 
are very laborious to synthesize compared to linear peptides175. Earlier, we reported a 
recombinant library of CII peptides expressed in E.coli using the foldon trimerization domain 
to create a triple helical structure67. The foldon-library was used to map new CII-epitopes in 
CIA. Unfortunately, the foldon domain originates from a bacterial phage176 to which humans 
have antibodies against. This highlights the need for synthetic peptides with defined epitopes 
to explore anti-CII antibodies as potential biomarkers in RA. 
A library of covalently branched THPs covering the 6 major B-cell epitopes in CII was 
synthesized. In addition to the native CII-sequence, citrullinated variants were made replacing 
the amino acid arginine with citrulline. The structure and purity of the THPs were confirmed 
by HPLC, Circular Dichroism (CD) spectroscopy, melting curve analysis and mass 
spectrometry. The mass spectrometry analysis showed that these are the largest THPs known 
to have been successfully characterized to date, showing molecular weights consistent with the 
theoretical weight both for the full THP and fragments after trypsin cleavage. The melting 
curve analysis demonstrated considerable variability in the melting temperature varying 
between 33.3-56.6 °C for the major epitopes. However, the differences could be explained by 
the individual peptide sequences, the F4 peptide in particular predicted to be more flexible177. 
The structural basis for forming a stable triple helix was dissected through introducing two 
different modifications to the C1 THP revealing that the simultaneous substitution of 
hydroxyproline (O) to proline (P) and the reduction of 5 to 2 GPO repeats abrogated the triple 
helical structure. Each modification independently did not have an effect on the ability of 
conformational anti-CII mAbs or serum from CII immunized mice to bind the C1 epitope. 
Next, the biotinylated THPs were coupled to Neutravidin coated magnetic beads and made into 
a multiplex array; comprised of all synthesized THPs and their cyclic controls. Subsequently, 
the triple helical structure of the peptides was confirmed through the binding of conformational 
dependent mAbs specific for C1, U1, F4 and D3 epitope. In addition, strong binding to all 
peptides was observed with serum from mice immunized with CII 21 days earlier but not from 
non-immunized mice. Our results from the mAb and CIA screenings determined a strong 
binding to all the major epitopes both in mAbs and mice sera, showing no cross-reactivity 
between THP and cyclic peptides confirming their triple helical structure.  
Finally, the THPs were evaluated in early RA patients cohorts TIRA-2 and BARFOT (n=2075) 
demonstrating a significantly higher antibody reactivity to C1, U1 and E10 epitope in RA 
patients compared to population controls (n=935) (Figure 8). 
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Figure 8 Antibody responses in sera from 
early-RA patients (n= 2075) and healthy 
controls (n= 935) to THPs containing the 
six native major CII epitopes. The MFI 
ratio has been calculated by dividing the 
MFI raw value with the median response 
to THP-control peptide (T_GPO_11). Cut-
off for positivity for each peptide was set 
at a median of healthy controls +3 standard 
deviations. [MFI = mean fluorescence 
intensity.] 
 
The results are consistent with our previous report that C1 and U1 are immunodominant B-cell 
epitopes both in primates, rodents and humans with arthritis67. Results from CIA, CAIA and 
cartilage explants have consistently demonstrated that antibodies targeting the C1 and U1 
epitopes are highly pathogenic171. For E10, this was the first report comparing the prevalence 
in RA and controls. We also confirmed that anti-CII antibodies specific for the F4 epitope are 
not associated with RA173,178, potentially explained by a regulatory function179.  
A cornerstone in the evaluation of biomarkers is consistent quality of the reagents to confirm 
results in independent cohorts. Reproducibility of the peptide synthesis was tested through the 
re-synthesis of three peptides; both batches of peptides showed consistent results in capturing 
anti-CII antibodies in serum. 
A limitation of this study is that it doesn’t analyze the response to specific epitopes with the 
clinical data for the patients. For instance, comparing the overlap to RF and ACPA may identify 
biomarkers for the “sero-negative” subset of patients. Finally, correlations to the disease 
development or treatment response may also yield new clinical biomarkers in RA. 
In summary, a library of THP covering the major B-cell epitopes in CII was synthesized and 
evaluated using anti-CII mAbs, serum from CIA and RA patients. Results confirmed their triple 
helical structure and revealed a more frequent response to the C1, U1 and E10 epitope in RA 
patients compared to population controls. 
4.3 STUDY III: A SHARED EPITOPE OF COLLAGEN TYPE XI AND TYPE II IS 
RECOGNIZED BY PATHOGENIC ANTIBODIES IN MICE AND HUMANS 
WITH ARTHRITIS 
CXI is a minor cartilage component which forms heterotrimers from three different chains, one 
of which is shared with CII. Rats immunized with homologous CXI in adjuvant develop a 
chronic relapsing arthritis phenotypically distinct from CIA81. As expected, increased titer of 
anti-CXI antibodies is observed in the chronic phase of the disease. Interestingly, antibodies 
against CXI have also been detected in RA patients93. However, the specificity and function of 
anti-CXI antibodies is not well understood. 
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We first assessed the arthritogenicity of immunization with CII or CXI in mice with the MHC 
H-2q haplotype. Immunization with CII leads to a severe arthritis with antibody response to 
CXI, particularly during the chronic stage. In contrast, CXI immunization induced only mild 
arthritis, with antibodies binding to CII detected primarily during the chronic stage. A panel of 
19 monoclonal antibodies specific for CXI were generated and assessed for cross-reactivity. 
This revealed that only the L10D9 clone binds both CXI and CII with similar affinity. Next, 
we demonstrated by screening with our CII-peptide library a strong binding of L10D9 to D3, 
a shared epitope between CXI and CII. Of 3 CXI clones evaluated in the CAIA model, only 
the CXI/CII cross-reacting clone L10D9 induced arthritis. In addition, L10D9 binds strongly 
to cartilage both in vivo and in vitro while the other 18 CXI clones displayed weak or no 
binding. Finally, the antibody response to the D3 epitope was tested in mice (CIA), rats (CIA, 
PIA) and the early RA cohort EIRA-1. Results showed significantly increased prevalence of 
anti-D3 antibodies in both RA patients and arthritic rodents compared to controls. The arthritis 
score in CII immunized mice was also shown to be positively correlated with the antibody 
response to the D3 epitope.  
Based solely on their structural similarity and co-localization in joints, it is surprising that 
immunization with CII and CXI or adoptive transfer of antibodies targeting them lead to such 
different phenotypes. The most plausible explanation is that CXI is hidden inside the collagen 
fibrils180, which is consistent with the very weak or non-existent binding to cartilage for 18 out 
of 19 tested CXI clones. As implicated in the chronic relapsing disease observed in rats, CXI 
cartilage may be exposed in the joints during chronic inflammation. If indeed CXI is hidden 
from the immune system, auto-reactive B and T-cells may not be efficiently negatively 
selected, further perpetuating the disease as new antigens are exposed during chronic stages of 
disease. Therefore, the major limitation in determining the arthritogenicity of the anti-CXI 
clones was that they were not tested in a chronic relapsing arthritis model. The unique 
characteristic of the L10D9 clone to induce arthritis is clearly linked to its ability to bind CII 
exposed on the cartilage surface. In addition, the results from this study confirm an earlier 
report that monoclonal antibodies directed against D3 epitope are pathogenic87. The finding 
that anti-D3 antibodies are present both in experimental arthritis models and RA argues for a 
potential role in the RA pathogenesis.  
In summary, this study has identified a shared epitope between CII and CXI, demonstrating the 
cross-reactivity between CII and CXI antibodies. The antibodies against the D3 epitope were 
recognized both in arthritic rodents and in RA patients.  
4.4  STUDY IV: ANTI-CITRULLINATED PROTEIN ANTIBODIES CAUSE 
ARTHRITIS BY CROSS-REACTIVITY TO JOINT CARTILAGE 
The immune response against citrulline starts several years before clinical onset of RA14. The 
production of ACPA is believed to originate at a mucosal tissue, eventually targeting the joints 
through a process of molecular mimicry and epitope spreading 148. There are several candidate 
autoantigens proposed to be involved during onset of the disease178,181, yet the structural basis 
of the cross-reactivity and the function of ACPA is not known. 
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To investigate the role of ACPA in the pathogenesis of RA, we examined the autoantibodies 
targeting the C1 epitope in CII. The C1 epitope contains two different arginine residues (R360, 
R365), the first shown to be citrullinated in vitro by PAD2178. The screening of the TIRA-2 
early RA cohort against a panel of triple helical and cyclic C1 peptides showed a significant 
response to all C1 peptides compared to controls, particularly against citrullinated variants of 
C1. The correlation between cyclic and THP citrullinated C1 response revealed a large overlap 
between them, with almost no patients exclusively binding to the triple helical citrullinated C1. 
Correlation between cyclic citrullinated C1 on the first position (Cit360) and CEP-1 showed 
43% of the patients to be double positive, although 22% of the patients were exclusively 
responding to only one of them.  
The major limitation in characterizing polyclonal antibodies in serum is that the cross-reactivity 
of individual clones cannot be determined. As a result, the correlation between two peptide 
responses in serum may be caused by two distinct subsets of antibodies. To examine the cross-
reactivity of ACPA binding citrullinated C1 we used the ACC1 monoclonal antibody reported 
earlier143. 
To determine the specificity of ACC1, we screened it against a library of CII-peptides, cyclic 
citrullinated peptide derived from filaggrin (CCP1) and the CCP2-kit. The screening revealed 
cross-reactivity to both native and citrullinated peptides of CII in addition to CCP1 and CCP2. 
The structural basis of the cross-reactivity was determined through crystalizing ACC1 with 
several different peptides, revealing a conserved peptide motif (RG-TG) present in all peptides. 
The motif is also found in other collagens. Examining this potential cross-reactivity revealed 
ACC1 binds CXI, identifying another shared epitope between CII and CXI as discussed in 
Study III. Finally, the arthritogenicity of ACC1 was determined by CAIA, showing it is one 
of the few reported clones which can induce arthritis when injected alone. 
In contrast to ACC1, most anti-CII antibodies are conformation dependent requiring a triple 
helical structure as shown in Study II and III. The ACPA binding THP in RA patients most 
likely target one of the α-chains in the THP which could explain the correlation between 
responses to triple helical and cyclic citC1. This is also the structural basis for how ACC1 can 
bind both triple helical and cyclic peptides as shown in the crystal structure complexes. While 
there are predictions for how flexible triple helical structures are based on their sequence177, 
how common “flexed out” α-chains are in the cartilage is not known. However, the strong 
binding of ACC1 to cartilage both in vitro and in vivo indicates it is a common feature, 
suggesting perhaps CII alternates between different conformational states. Measurements by 
CD-spectroscopy and melt-curve analysis in Study II also show that substituting arginine for 
citrulline destabilizes the peptides. As a result, citrullination in vivo will destabilize the triple 
helical structure exposing it to be targeted by ACPA.  
In summary, we demonstrate the molecular mechanism for cartilage binding and arthritis 




4.5 STUDY V: STRUCTURAL BASIS OF CROSS-REACTIVITY OF ANTI-
CITRULLINATED PROTEIN ANTIBODIES 
The current method for determining the presence of ACPA to diagnose RA patients uses a set 
of undisclosed synthetic peptides, where response above or below a certain cut-off determines 
if they are ACPA positive or negative13. However, the quest to identify citrullinated 
autoantigens involved in the pathogenesis has revealed that ACPA are a very heterogenous 
class of antibodies, ranging from a promiscuous binding pattern recognizing peptides of diverse 
origin182, to a single citrullinated epitope143. This cross-reactivity between citrullinated epitopes 
of different proteins is a pillar in the current dogma that molecular mimicry and epitope 
spreading starting in the mucosal tissue leads to an autoimmune disease targeting the joints. At 
the same time, the basis for this cross-reactivity has not been understood. 
In Study V, we set out to characterize the structural basis of cross-reactivity in ACPA. First, 
clones isolated from RA patients were screened on a library of cyclic citrullinated peptides and 
corresponding controls. The E4 and F3 clones showed a partially overlapping binding profile, 
with E4 being more diverse. In contrast, the D10 and B2 clones did not show binding to any 
peptides included in our screen. Next, the E4 clone was crystalized together with three different 
citrullinated peptides; two citrullinated CII peptides and CEP-1 derived from α-enolase. The 
crystal structure revealed a “pocket” for the non-polar citrulline residue. In contrast, the polar 
amino acid arginine is a is not modelled to fit in this pocket due to its positive charge. The 
crystal structure also showed other interactions predicting which adjacent amino acids were 
preferred, explaining the specific peptide binding pattern observed for E4. On the other hand, 
the crystal structures of D10 and B2 without peptide displayed a very different structure, 
explaining why they do not bind any citrullinated peptides in our assay. 
The “pocket” for a citrulline residue in E4 also provides a model for how an ACPA may cross-
react to the structurally similar homocitrulline, which is the target for anti-carbamylated protein 
antibodies (anti-CarP), shown to cross-react with citrullinated peptides183. Accordingly, our 
report supports the growing body of evidence that many ACPA in RA are probably best 
described as AMPA: anti-modified protein antibody. 
Finally, the prevalence of antibodies against the three crystallized peptides with E4 were 
evaluated in the TIRA-2 and EIRA-1 early RA cohorts. The individual peptides were 
recognized in between 40-68% of RA patients, with around 1/3 positive for all three peptides. 
In summary, we demonstrate for the first time the structural basis for how a human ACPA can 





In Study I, periodontitis induced P.gingivalis did not affect the development or disease severity 
of PIA in rats. On the other hand, the group with established periodontitis showed increased 
levels of antibodies against a citrullinated P.PAD peptide. This finding supports the first step 
in the hypothesized link between P.gingivalis and RA; a citrulline specific immune response 
against a bacterial protein. 
A library of THP covering the major B-cell epitopes in CII was successfully synthesized in 
Study II. The synthesized peptides confirmed earlier reports of C1 and U1 as the two 
immunodominant CII-epitopes for antibodies in RA. 
In Study III, the L10D9 clone binding CXI was shown to induce arthritis by cross-reacting to 
the D3 epitope shared with CII. Antibody reactivity against the D3 epitope was observed both 
in serum of arthritic rodents and RA patients. 
In Study IV, an ACPA was demonstrated to induce arthritis by binding a conserved structural 
motif on native CII shared with both CCP1 and CCP2. 
In Study V, a human ACPA was crystallized with citrullinated peptides from different proteins 
demonstrating that the cross-reactivity was due to a specific recognition of citrulline in a 




6 FUTURE PERSPECTIVES 
Hundreds of articles investigating RA are published annually, yet the growing body of evidence 
indicates that we are just beginning to understand the complexity of RA and other autoimmune 
diseases. The number of genetic risk loci associated with RA are now over 10023 and it would 
be naïve to think we have identified all of them. From the perspective of environmental risk 
factors, our work support a potential role of P.gingivalis in RA pathogenesis, although it is 
unclear if  animal models will ever be able to confirm the theory. This idea of a microbial origin 
of autoimmunity isn’t new. In fact, this elegant theory has captured the imagination of countless 
scientists over the years. The scientific curiosity ignited by this concept has resulted in studies 
such as the X-ray examination of ancient mummies in search for the earliest signs of RA58.  
A recent review of the association of RA and the two oral pathogens P.gingivalis and Aa. 
proposed to induce citrullination cited 233 papers with majority of them less than a decade 
old47. Sorting through the wealth of data that this single hypothesis has generated since 2004 is 
staggering, let alone trying to integrate it with all the other theories about the etiology of RA184. 
How is it possible to reconcile all the implicated genes, environmental risk factors and epistatic 
interactions between them in one model the human mind can grasp? Not to mention all the 
proposed autoantigens being targeted both in their native form and with PTMs such as 
citrulline, homocitrulline and acetyl119,120. One explanation may be that we are not dealing with 
a single disease with a distinct etiology: it is rather a collection of diseases with common 
clinical endpoint185. 
The solution may in that case be in redefining the very concept of RA. Just as the classification 
criterion in 1957, 1987 and 2010 led to an updated view of what RA was, the insights gained 
during the last decade may soon warrant a new update. One striking observation is that the 
ACPA+ subset of patients appears to be separate disease with a different etiology compared to 
ACPA- RA. Although even within the ACPA+ subset there is large degree of phenotypic 
variation, in particular during the early stages. The heterogeneity observed indicates more 
subtypes of RA may exist, possibly linked to different initiating causes and genetic risk factors. 
The identification of additional subtypes is also likely to provide more efficient treatment 
strategies for separate subtypes. This is by no means a unique observation, much of the research 
today is directed towards explaining the phenotypic variation by correlating them to a wide 
range of biomarkers, genes and environmental risk factors. 
Finding new distinct subtypes is by no means an easy task. Based on observations in this thesis 
an attractive target may be to define the subsets of antibodies associated with the onset of 
disease. To date, only antibodies binding cartilage has been conclusively shown to induce 
arthritis. For instance, antibodies associated with the onset of disease may be used as a 
biomarker to define a subtype of patients for new therapeutic strategies aimed at depleting186, 
neutralizing187 or modulating188 arthritogenic antibodies which could reduce symptoms such as 
antibody mediated pain86. While the role B-cells during the onset of disease is not clarified, the 
subset of patients with joint-reactive antibodies may also be of benefit of B-cell depletion 
 
34 
therapy189 currently mainly used during a later stage of disease after other treatments have 
failed. If the success of anti-B-cell therapy is related to depletion joint-reactive B-cells it may 
explain why clinical effect is not seen in all patients.  
Finally, in addition to addressing symptoms such as of acute pain during the onset of disease, 
early therapeutic interventions also have the potential to prevent RA from becoming 
established. However, the window of opportunity for such interventions is likely to be narrow, 
and specific biomarkers to identify the patients and the appropriate treatment strategies in time 




During this long journey there are many people I would like to thank: 
My supervisor Rikard, thank you for giving me this great opportunity. You have since the start 
trusted me with a large degree of freedom to explore new ideas and follow my curiosity. The 
project plan you wrote couldn’t have been more suited for my interests. In addition to your 
deep knowledge in immunology, it’s always interesting to discuss current and historical events 
with you, your broad knowledge has been an inspiration to me. 
My co-supervisor Chris, thank you for all the encouraging phone calls along the journey. I was 
disappointed that we never got the epitope induced project to work, but it turns it wasn’t our 
fault, it was the mice! I really hope we can follow up on the JIA-cohort soon! 
My co-supervisor Nan, thank you for always making the seminar and projects lively with your 
questions and for your help during my visit in Guangzhou. 
The person who in a sense recruited me to the lab was however Jonatan. In his search for 
unpaid labor to assist him in his grand sequencing efforts he took me in for my exam project. 
At the time of reading your ad I had no idea it would be a major crossroad coming to define 
my life. You entrusted me both with your machine (ABI3730 sequencer) and your teaching 
duty (lipid lab). Sabrina, you were together with JT my role models of how I imagined a PhD-
student should be. Nice memories from late evenings in the kitchen. Your PhD-defense is to 
date the best I’ve ever witnessed. Anthony, thank you very much for showing me your college 
at Oxford and for all the friendly chats over the years. I still recall your two first observations 
about what surprised you about Stockholm, the first was all the prams in public transport, the 
second was that there were so many people wearing school uniforms. Turned out that you had 
mistaken the logo of a very popular clothes brand with the insignia of a school. 
Johan, for your big patience with me and my smoking machine and the work with all the 
permits. I didn’t understand the full extent of your hard work over the years until I summarized 
all of them for my PhD application. Kajsa, for your kindness and big efforts to organize the 
lab. Liselotte for not making me be the only Stockholmer in lab, agreeing to be the dissertation 
chairman, friendly chats over the years and organizing the move to Biomedicum. In addition, 
taking on the daunting task to be responsible for the animal house. Biborka for your 
encouraging words and teaching me about Hungarian culture. Emma, for teaching me 
histology and reminding me to eat healthy. Cecilia, for not being afraid to speak your mind. 
Angel, for being the glue holding together the organisation, I’ve really enjoyed the social 
gatherings you put a lot of effort into organizing over the years. Bingze is another steady rock 
in the lab, catering to all our monoclonal expression needs over the years and helping out with 
the Chinese New Year celebrations. Min Y for the development of the GPI-project and being 
an excellent office mate. One of my favorite office mates over the years is Susann W, many 
great conversions about life and science. In addition, a healthy dose German efficiency to keep 
the office a good working environment. Susanne vdB was another source of order and 
 
36 
efficiency. I still regret to this day when you helped me borrow a spin-column from a 
neighbouring lab and I failed to give it back when we got a restock. It was refreshing to see 
someone above 35 who had a strong passion for exploring the world. Hanane for giving me 
new perspectives and being friend during the entire course of my PhD, with encouraging 
messages to boost morale. In addition, great help in revising the thesis! 
Vilma, for making me the honor to join me for lunch on so many occasions, discussing 
everything from vaccinations to Eastern European customer service. In addition, you also taken 
some very nice photos of me! Hüseyin for supervising me in the development of the foldon-
library and your paper on ACPA. To date, this is the single paper I’ve conferred to the greatest 
number of times. Ingrid, for entrusting me with taking care of the foldon-manuscript, and Ida 
for helping sort out the protein purification. Changrong, for great help in the diagnostics 
project, always being open to try new ideas and (attempting) to teach me SIMCA. You 
openminded attitude has helped me understand nuances of Chinese culture. I’m glad that you 
introduced me to Lei who has been instrumental to moving the diagnostic project forward. Big 
thanks to Silvia for taking on a big responsibility coordinating the diagnostics project and 
speaking your mind. Markus H for great discussions about science, life and beyond. In 
addition, to our grand plans on how to dissect the molecular mechanism of PIA. Mika F for 
attending some great movies with me, inspiring me to get body of Dolph Lundgren in his prime 
(next year, I promise!), listen to my speculations over lunch, often joined by Sara LE, whose 
reaction upon learning that I’m good friends with her husband’s cousin Harald E was 
priceless! Harald E also once a fellow PhD-student, who indirectly taught me a lot over the 
years by asking medical questions I needed to do literature searches for and introducing me to 
concepts like Autoimmune protocol diet and biohackers engaged in experimental self-
treatments of autoimmune diseases. Patrick M for interesting conversations ranging from 
rodent lactation to bi(tri)lingualism in kids. Franziska for being another great example that 
research can be combined with kids. Bruno, for challenging my pre-conceived idea about 
Southern Europeans being loud and not working hard. Ia for discussions during project 
meetings and our shared interest in mannan. Martina for entrusting me the Ym1 project and 
our experiments together. Craig for helping me make emulsions and sharing your wisdom and 
experiences from Barbados. Carlos for chorizo, tennis and animal care. He also was helped by 
Kristina, Tomek, Evelina and Jinlian. 
Bibo, for helping me setup the Luminex assay and your helping hand when I visited 
Guangzhou. Dongmei, for attempting to introducing me to Chinese culture during long 
experiments in the animal house. In return I was glad to introduce you to the Swedish cray-fish 
party! I cannot thank you enough for helping to organize our trip to Beijing! Lilu and for a 
friendly smile and nice chats. Naru for giving me company to explore Gothenburg that time 
when we got stranded there. Wenhua for taking on the Ym1 project and getting it published. 
I’m very sorry I haven’t learned yet how to pronounce your name. Liesu for always having a 
bright smile and helping to keep Ulle sane by helping out in her project. Ulle I also need to 
thank for helping me organize cray-fish party and entrusting the periodontitis project in my 
hands. John/Jianghong, for many interesting conversations over the years and putting up with 
 
 37 
Amit who is my (bestest) friend. The lunches we have prepared and shared over the years are 
more than with any adult during my lifetime. All the talks about bregs, cricket, Pakistan, time-
to-do-your-halftime and life over the years, not to mention all time in the animal house together. 
There is still a void after you left. 
Katrin for all the amazing cakes and your “nom nom I love p…” impersonation of a mouse 
ruining your experiments during one of your seminars. The balcony we had at the Scheele 
laboratory was amazing. Many great evenings with Florian the couch-mover, the charismatic 
Clara. Danielle for a frank and positive attitude and our trip to Beijing. Simon has been a great 
friend over the years, you helped me in my darkest hour to try to address the basic immunology 
in my early mouse experiments. Many nice memories, in particular with all our trips with the 
research school. Big thanks reviewing the thesis! Several of those occasions also in the 
presence of Joanna and Milind which I’m very glad to have shared my PhD experience with. 
Outi, for the initial help setting up the diagnostic project, and now returning to save us! Thanks 
again for inviting me to your house in Turku, my understanding of Finnish culture is to a large 
extent based on this experience.  
Mike A, you Old World monkey! Thanks for lending me some awesome books to broaden my 
mind. Always interesting to discuss a wide range of topics, from the Lebanese banking system 
to strategies for Settler of Catan and recent papers in immunology. Gonzalo, for good 
discussions after seminars and the ability to keep your head cool. With exception of the epic 
taxi-ride in Beijing. Thanks for being there to share the best dumplings ever. Yibo, for our 
discussions about regulatory mechanisms of ACPA, life and shared lifestyle. Jaime, for always 
allowing me to have a moment of your time, reviewing the thesis samt någon att prata svenska 
med. Michael B, Dear Sir, thanks for reviewing the thesis and discussions on life and science. 
Taotao, you have done an impressive work on the projects we have been working on! Alex K 
for bringing some German efficiency into the lab and being open to discuss new ideas. Weiwei 
for help in many projects. Huqiao for future collaboration on PIL! Zhongwei for help with 
technical issues during presentation and together with Alex M driving the F4-project forward. 
Laura and Rajan to bring some much-needed experience to the lab and helping out in mapping 
T-cell responses. Ana, for making high quality company over lunch and introducing me to 
Gazela! 
The best part about moving to Biomedicum is the increased interaction with people on the same 
floor. Pierre and Christian for providing excellent lunch company in the absence of Amit, 
introducing me to ESA sushi and that ramen place! Amir for great conversations about science 
and life while exposing me to secondhand smoke. Hassan for being open minded and sharing 
with me his entrepreneurial ideas (I promise I won’t steal them). Susanna L for helping out 
with various glycosylations analysis over the years and being the person to introduce me to 
surströmming! Natasha Ö(T) for good conversions over the years and great kids parties! 
Happy for you and Linus, although to be frank Munchkin is not my favourite boardgame… 
 
38 
The worst part about moving to Biomedicum is that there is no really good meeting point to 
gather after a hard day of work. This, in addition to the birth of my son has led to me spending 
less time socializing in the lab. Therefore, I have not gotten to know many of our new lab 
members very well, Xiaojie, Meng, Chang, Qijing but I hope to get new opportunities to get 
to know you once my PhD studies come to an end. 
The National Clinical Sesearch School in Chronic Inflammatory Diseases was one of the best 
experiences during my PhD. Very grateful to Helena H and Jan A for organizing it. Lots of 
great courses and conferences. 
Test subjects 
Over 10 000 different patient samples were analyzed during my PhD, I’m very thankful for 
those that have taken time to donate samples for research. 
I also want to acknowledge all animal which were sacrificed during the duration of my PhD, 
and all the students that were taught under my supervision. 
Collaborators 
Speaking of teaching, I want to thank my colleagues at the lipid lab, in particular Lars, Will, 
and Frank. 
At CMM there were a great deal of researchers in rheumatology I met during various 
collaborations, conferences and courses. Vivianne Malmström, Karin Lundberg, Lena 
Israelsson, Monica Hansson, Natalia S, Rita, Jorge and Espen to name a few. 
Big thanks to Tulay, Kaja, Pierre, Greg and Anna K for the work on the periodontitis project. 
It was a pleasure working with you, very good working atmosphere despite the long 15-week 
experiment. 
At Sci-life Burcu and Peter were kind enough to let us use their Luminex platform to establish 
our diagnostic project. Big thanks for all the support and kind advice, the work based on it has 
been an important part of my PhD! 
Several project would not have been possible without a collaboration with clinicans all over 
the world that have provided samples: Alf Kastbom, Christopher Sjöwall and Thomas 
Skogh for Kluring, TIRA-2 and TIRx, Lars Klareskog for EIRA, Solbritt Rantapää 
Dahlqvist for Umea pre-RA, Harald Burkhardt for PANORA and XCITING to name a few. 
Finally, Inger Gjertsson who in addition to providing the BARFOT samples has been 
instrumental for establishing and developing the diagnostic project. Thank you for giving me 
the clinician’s perspective to my research and organizing nice visits in Gothenburg. In your 
group I would also like to thank Monica, Karin, Lollo and Charlotte for all the shared projects 
over the years! 
 
 39 
In Uppsala, Jan Kihlberg and Johan Viljanen has worked hard to design and synthesize triple 
helical peptides in a volume never seen before. We now have reagents for years to come and I 
hope they will come to good use. 
Friends and family 
Olof, du har varit min intellektuella förbundsförvant i över 30 år. Stort tack for alla diskussioner 
under min doktorandperiod för att sätta saker i perspektiv och utveckla nya idéer. Nu senast 
om bio-elektricitet och för inspirationen för avhandlingens utformning. 
Till mina föräldrar, Jan-Olof och Eva som stöttat mig under åren under min väldigt långa tid 
som student. Utan er hjälp hade det inte varit möjligt. Ni har senaste 5 åren varit ett levande 
bevis för hypotesen ”grandmother hypothesis” om mor- och farföräldrar som hjälper sina 
barnbarn. Min bror Stefan, som hjälpte mig installera rökmaskinen, och hjälpt till med tekniska 
spörsmål under åren. 
Slutligen, till min alldeles egna kärnfamilj. Gabriella och Ivar som har skänkt mig så mycket 
glädje under de senaste åren, om än till kostnad av kronisk sömnlöshet. Men inget vore möjligt 
utan mitt livs kärlek Nastya. Din första insats var att hjälpa mig sätta ihop en presentation på 
SSI-konferensen i Reykjavik där jag missat att läsa den finstilta texten att jag blivit utvald till 
att hålla ett muntligt föredrag. Jag fick panik men du hjälpte mig kvällen innan sätta ihop en 
presentation på din dator. Sedan dess har du alltid funnits vid min sida.  
 
 
The list above is by no means complete. I would also like to acknowledge all of those I’ve 
forgotten to mention that have contributed to my PhD-project over the years. Finally, I would 
like to sincerely thank everyone that has made the effort of reading through my thesis, it’s my 






1.  Cooper MD, Alder MN. The evolution of adaptive immune systems. Cell. 
2006;124(4):815-822. doi:10.1016/j.cell.2006.02.001 
2.  Cascales E, Buchanan SK, Duché D, et al. Colicin Biology. Microbiology and 
Molecular Biology Reviews. 2007;71(1):158-229. doi:10.1128/mmbr.00036-06 
3.  Beutler B. Innate immunity: An overview. Molecular Immunology. 2004;40(12):845-
859. doi:10.1016/j.molimm.2003.10.005 
4.  Calil IP, Fontes EPB. Plant immunity against viruses: Antiviral immune receptors in 
focus. Annals of Botany. 2017;119(5):711-723. doi:10.1093/aob/mcw200 
5.  Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. 
In: Cold Spring Harbor Symposia on Quantitative Biology. Vol 54. Cold Spring 
Harbor Laboratory Press; 1989:1-13. doi:10.1101/sqb.1989.054.01.003 
6.  Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. 
Experimental and Molecular Medicine. 2013;45(12):45. doi:10.1038/emm.2013.97 
7.  Hardison SE, Brown GD. C-type lectin receptors orchestrate antifungal immunity. 
Nature Immunology. 2012;13(9):817-822. doi:10.1038/ni.2369 
8.  Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci 
KR. Pattern recognition receptors and the host cell death molecular machinery. 
Frontiers in Immunology. 2018;9(OCT):2379. doi:10.3389/fimmu.2018.02379 
9.  Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation. Cell. 
2010;140(6):805-820. doi:10.1016/j.cell.2010.01.022 
10.  Cooper MD, Alder MN. The evolution of adaptive immune systems. Cell. 
2006;124(4):815-822. doi:10.1016/j.cell.2006.02.001 
11.  Brazeau MD, Friedman M. The origin and early phylogenetic history of jawed 
vertebrates. Nature. 2015;520(7548). doi:10.1038/nature14438 
12.  Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. 
Nature Immunology. 2017;18(7):716-724. doi:10.1038/ni.3731 
13.  Schellekens GA, Visser H, de Jong BAW, et al. THE DIAGNOSTIC PROPERTIES 
OF RHEUMATOID ARTHRITIS ANTIBODIES RECOGNIZING A CYCLIC 
CITRULLINATED PEPTIDE. Vol 43.; 2000. doi:10.1002/1529-0131 
 
42 
14.  Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against 
citrullinated peptides in individuals prior to development of rheumatoid arthritis. 
Arthritis and Rheumatism. 2013;65(4):899-910. doi:10.1002/art.37835 
15.  Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: Diagnostic Accuracy of 
Anti–Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid 
Arthritis. Annals of Internal Medicine. 2007;146(11):797. doi:10.7326/0003-4819-
146-11-200706050-00008 
16.  Padyukov L, Alfredsson L. Gene-gene and gene-environment interaction in 
rheumatoid arthritis. In: Between the Lines of Genetic Code: Genetic Interactions in 
Understanding Disease and Complex Phenotypes. Elsevier Inc.; 2013:85-100. 
doi:10.1016/B978-0-12-397017-6.00005-2 
17.  Lipsky PE, van der Heijde DMFM, st. Clair EW, et al. Infliximab and Methotrexate in 
the Treatment of Rheumatoid Arthritis. New England Journal of Medicine. 
2000;343(22):1594-1602. doi:10.1056/nejm200011303432202 
18.  ROPES MW, BENNETT GA, COBB S, JACOX R, JESSAR RA. Proposed 
diagnostic criteria for rheumatoid arthritis. Annals of the rheumatic diseases. 
1957;16(1):118-125. doi:10.1136/ard.16.1.118 
19.  Arnett FC, Edworthy SM, Bloch DA, et al. The american rheumatism association 1987 
revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism. 
1988;31(3):315-324. doi:10.1002/art.1780310302 
20.  MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic 
contribution to rheumatoid arthritis using data from twins. Arthritis and Rheumatism. 
2000;43(1):30-37. doi:10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B 
21.  Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. an approach to 
understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis 
& Rheumatism. 1987;30(11):1205-1213. doi:10.1002/art.1780301102 
22.  Wysocki T, Olesińska M, Paradowska-Gorycka A. Current Understanding of an 
Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to 
Clinical Practice. Cells. 2020;9(5). doi:10.3390/cells9051127 
23.  Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to 
biology and drug discovery. Nature. 2014;506(7488):376-381. 
doi:10.1038/nature12873 
24.  Ding B, Padyukov L, Lundström E, et al. Different patterns of associations with anti-
citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative 
rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis 
and Rheumatism. 2009;60(1):30-38. doi:10.1002/art.24135 
 
 43 
25.  Mikuls TR, Payne JB, Deane KD, Thiele GM, Lincoln O, Colo A. Autoimmunity of 
the lung and oral mucosa in a multisystem inflammatory disease: The spark that lights 
the fire in rheumatoid arthritis? Published online 2016. doi:10.1016/j.jaci.2015.10.024 
26.  Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Current 
Opinion in Rheumatology. 2010;22(2):109-118. doi:10.1097/BOR.0b013e328336474d 
27.  Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex 
diseases. Nature. 2009;461(7265):747-753. doi:10.1038/nature08494 
28.  Jonsson H, Magnusdottir E, Eggertsson HP, et al. Differences between germline 
genomes of monozygotic twins. Nature Genetics. 2021;53(1):27-34. 
doi:10.1038/s41588-020-00755-1 
29.  Nyhäll-Wåhlin BM, Jacobsson LTH, Petersson IF, Turesson C. Smoking is a strong 
risk factor for rheumatoid nodules in early rheumatoid arthritis. Annals of the 
Rheumatic Diseases. 2006;65(5):601-606. doi:10.1136/ard.2005.039172 
30.  Rydell E, Forslind K, Nilsson JÅ, Jacobsson LTH, Turesson C. Smoking, body mass 
index, disease activity, and the risk of rapid radiographic progression in patients with 
early rheumatoid arthritis. Arthritis Research and Therapy. 2018;20(1). 
doi:10.1186/s13075-018-1575-2 
31.  Svärd A, Skogh T, Alfredsson L, et al. Associations With Smoking and Shared 
Epitope Differ Between IgA- and IgG-Class Antibodies to Cyclic Citrullinated 
Peptides in Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2015;67(8):2032-
2037. doi:10.1002/art.39170 
32.  Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette 
smoking on rheumatoid arthritis: Results from a population based case-control study, 
using incident cases. Annals of the Rheumatic Diseases. 2003;62(9):835-841. 
doi:10.1136/ard.62.9.835 
33.  Heliövaara M, Aho K, Knekt P, Reunanen A. Smoking and risk of rheumatoid 
arthritis. J Rheumatol. 1993;20(11):1830-1835. Accessed May 17, 2021. 
https://pubmed.ncbi.nlm.nih.gov/8308766/ 
34.  van der Woude D, Alemayehu WG, Verduijn W, et al. Gene-environment interaction 
influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid 
arthritis. Nature Genetics. 2010;42(10):814-816. doi:10.1038/ng1010-814 
35.  Mahdi H, Fisher BA, Källberg H, et al. Specific interaction between genotype, 
smoking and autoimmunity to citrullinated α-enolase in the etiology of rheumatoid 
arthritis. Nature Genetics. 2009;41(12):1319-1324. doi:10.1038/ng.480 
 
44 
36.  Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and 
environmental risk factors for multiple sclerosis. Nature Reviews Neurology. 
2016;13(1):26-36. doi:10.1038/nrneurol.2016.187 
37.  Gomes JP, Watad A, Shoenfeld Y. Nicotine and autoimmunity: The lotus’ flower in 
tobacco. Pharmacological Research. 2018;128:101-109. 
doi:10.1016/j.phrs.2017.10.005 
38.  Lee J, Luria A, Rhodes C, et al. Nicotine drives neutrophil extracellular traps 
formation and accelerates collagen-induced arthritis. Rheumatology. 
2016;56(4):kew449. doi:10.1093/rheumatology/kew449 
39.  Joo SH, Lee J, Hutchinson D, Song YW. Prevalence of rheumatoid arthritis in relation 
to serum cadmium concentrations: Cross-sectional study using Korean National Health 
and Nutrition Examination Survey (KNHANES) data. BMJ Open. 2019;9(1). 
doi:10.1136/bmjopen-2018-023233 
40.  Fu J, Nogueira S v., van Drongelen V, et al. Shared epitope–aryl hydrocarbon receptor 
crosstalk underlies the mechanism of gene–environment interaction in autoimmune 
arthritis. Proceedings of the National Academy of Sciences of the United States of 
America. 2018;115(18):4755-4760. doi:10.1073/pnas.1722124115 
41.  Murphy D, Hutchinson D. Is Male Rheumatoid Arthritis an Occupational Disease? A 
Review. The Open Rheumatology Journal. 2017;11(1):88-105. 
doi:10.2174/1874312901711010088 
42.  Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 
sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global 
Burden of Disease Study 2010. The Lancet. 2012;380(9859):2163-2196. 
doi:10.1016/S0140-6736(12)61729-2 
43.  Sayehmiri F, Sayehmiri K, Asadollahi K, et al. The prevalence rate of Porphyromonas 
gingivalis and its association with cancer: A systematic review and meta-analysis. 
International Journal of Immunopathology and Pharmacology. 2015;28(2):160-167. 
doi:10.1177/0394632015586144 
44.  McGraw WT, Potempa J, Farley D, Travis J. Purification, characterization, and 
sequence analysis of a potential virulence factor from Porphyromonas gingivalis, 
peptidylarginine deiminase. Infection and Immunity. 1999;67(7):3248-3256. 
doi:10.1128/iai.67.7.3248-3256.1999 
45.  Potempa J, Mydel P, Koziel J. The case for periodontitis in the pathogenesis of 




46.  Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis: The humoral 
immune response to oral bacteria provides a stimulus for the development of 
rheumatoid arthritis. Inflammation. 2004;28(6):311-318. doi:10.1007/s10753-004-
6641-z 
47.  Gómez-Bañuelos E, Mukherjee A, Darrah E, Andrade F. Rheumatoid Arthritis-
Associated Mechanisms of Porphyromonas gingivalis and Aggregatibacter 
actinomycetemcomitans. Journal of Clinical Medicine. 2019;8(9):1309. 
doi:10.3390/jcm8091309 
48.  Bingham CO, Moni M. Periodontal disease and rheumatoid arthritis: The evidence 
accumulates for complex pathobiologic interactions. Current Opinion in 
Rheumatology. 2013;25(3):345-353. doi:10.1097/BOR.0b013e32835fb8ec 
49.  How KY, Song KP, Chan KG. Porphyromonas gingivalis: An overview of 
periodontopathic pathogen below the gum line. Frontiers in Microbiology. 
2016;7(FEB):53. doi:10.3389/fmicb.2016.00053 
50.  Konig MF, Abusleme L, Reinholdt J, et al. Aggregatibacter actinomycetemcomitans-
induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid 
arthritis. Science Translational Medicine. 2016;8(369):369ra176. 
doi:10.1126/scitranslmed.aaj1921 
51.  Queiroz-Junior CM, Madeira MFM, Coelho FM, et al. Experimental arthritis 
exacerbates Aggregatibacter actinomycetemcomitans- induced periodontitis in mice. 
Journal of Clinical Periodontology. 2012;39(7):608-616. doi:10.1111/j.1600-
051X.2012.01886.x 
52.  Simpson DL, Berthold P, Taichman NS. Killing of human myelomonocytic leukemia 
and lymphocytic cell lines by Actinobacillus actinomycetemcomitans leukotoxin. 
Infection and Immunity. 1988;56(5):1162-1166. doi:10.1128/iai.56.5.1162-1166.1988 
53.  DiFranco KM, Kaswala RH, Patel C, Kasinathan C, Kachlany SC. Leukotoxin kills 
rodent WBC by targeting leukocyte function associated antigen 1. Comparative 
Medicine. 2013;63(4):331-337. Accessed May 6, 2021. /pmc/articles/PMC3750668/ 
54.  Engström M, Eriksson K, Lee L, et al. Increased citrullination and expression of 
peptidylarginine deiminases independently of P. gingivalis and A. 
actinomycetemcomitans in gingival tissue of patients with periodontitis. Journal of 
Translational Medicine. 2018;16(1). doi:10.1186/s12967-018-1588-2 
55.  Gomez-Bañuelos E, Johansson L, Konig M, et al. Exposure to Aggregatibacter 
actinomycetemcomitans before Symptom Onset and the Risk of Evolving to 




56.  Mukherjee A, Jantsch V, Khan R, et al. Rheumatoid arthritis-associated autoimmunity 
due to Aggregatibacter actinomycetemcomitans and its resolution with antibiotic 
therapy. Frontiers in Immunology. 2018;9(OCT). doi:10.3389/fimmu.2018.02352 
57.  Volkov M, Dekkers J, Loos BG, et al. Comment on “Aggregatibacter 
actinomycetemcomitans-induced hypercitrullination links periodontal infection to 
autoimmunity in rheumatoid arthritis.” Science Translational Medicine. 2018;10(433). 
doi:10.1126/scitranslmed.aan8349 
58.  Kwiecinski J, Rothschild BM. No rheumatoid arthritis in ancient Egypt: a reappraisal. 
Rheumatology International. 2016;36(6):891-895. doi:10.1007/s00296-015-3405-z 
59.  Lotz M, Roudier J. Epstein-Barr virus and rheumatoid arthritis: cellular and molecular 
aspects. Rheumatology International. 1989;9(3-5):147-152. doi:10.1007/BF00271872 
60.  Svendsen AJ, Westergaard MCW, Draborg AH, et al. Altered Antibody Response to 
Epstein-Barr Virus in Patients With Rheumatoid Arthritis and Healthy Subjects 
Predisposed to the Disease. A Twin Study. Frontiers in Immunology. 2021;12:650713. 
doi:10.3389/fimmu.2021.650713 
61.  Trier N, Izarzugaza J, Chailyan A, Marcatili P, Houen G. Human MHC-II with shared 
epitope motifs are optimal Epstein-Barr virus glycoprotein 42 ligands—relation to 
rheumatoid arthritis. International Journal of Molecular Sciences. 2018;19(1). 
doi:10.3390/ijms19010317 
62.  Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. 
Scandinavian Journal of Rheumatology. 2006;35(3):169-174. 
doi:10.1080/03009740600718080 
63.  Symmons DPM, Bankhead CR, Harrison BJ, et al. Blood transfusion, smoking, and 
obesity as risk factors for the development of rheumatoid arthritis: Results from a 
primary care-based incident case-control study in Norfolk, England. Arthritis and 
Rheumatism. 1997;40(11):1955-1961. doi:10.1002/art.1780401106 
64.  Ebringer A, Rashid T. Rheumatoid arthritis is an autoimmune disease triggered by 
Proteus urinary tract infection. doi:10.1080/17402520600576578 
65.  di Lullo GA, Sweeney SM, Körkkö J, Ala-Kokko L, San Antonio JD. Mapping the 
ligand-binding sites and disease-associated mutations on the most abundant protein in 
the human, type I collagen. Journal of Biological Chemistry. 2002;277(6):4223-4231. 
doi:10.1074/jbc.M110709200 
66.  Bella J. Collagen structure: New tricks from a very old dog. Biochemical Journal. 
2016;473(8):1001-1025. doi:10.1042/BJ20151169 
67.  Lindh I, Snir O, Lönnblom E, et al. Type II collagen antibody response is enriched in 
the synovial fluid of rheumatoid joints and directed to the same major epitopes as in 
 
 47 
collagen induced arthritis in primates and mice. Arthritis Research and Therapy. 
2014;16(4). doi:10.1186/ar4605 
68.  von der Mark K. Structure, Biosynthesis and Gene Regulation of Collagens in 
Cartilage and Bone. In: Dynamics of Bone and Cartilage Metabolism. Elsevier Inc.; 
2006:3-40. doi:10.1016/B978-012088562-6/50002-9 
69.  Ericsson AC, Crim MJ, Franklin CL. A brief history of animal modeling. Missouri 
medicine. 2013;110(3):201-205. Accessed February 3, 2021. 
/pmc/articles/PMC3979591/?report=abstract 
70.  Mestas J, Hughes CCW. Of Mice and Not Men: Differences between Mouse and 
Human Immunology. The Journal of Immunology. 2004;172(5):2731-2738. 
doi:10.4049/jimmunol.172.5.2731 
71.  Animal models used by 186 of 222 recipients of Nobel Price in Medicine. Accessed 
February 3, 2021. https://fbresearch.org/medical-advances/nobel-prizes/ 
72.  Barré-Sinoussi F, Montagutelli X. Animal models are essential to biological research: 
Issues and perspectives. Future Science OA. 2015;1(4). doi:10.4155/fso.15.63 
73.  Holmdahl R, Bockermann R, Bäcklund J, Yamada H. The molecular pathogenesis of 
collagen-induced arthritis in mice - A model for rheumatoid arthritis. Ageing Research 
Reviews. 2002;1(1):135-147. doi:10.1016/S0047-6374(01)00371-2 
74.  Bäcklund J, Li C, Jansson E, et al. C57BL/6 mice need MHC class II Aq to develop 
collagen-induced arthritis dependent on autoreactive T cells. Annals of the Rheumatic 
Diseases. 2013;72(7):1225-1232. doi:10.1136/annrheumdis-2012-202055 
75.  Vierboom MPM, Breedveld E, Kondova I, ’t Hart BA. Collagen-induced arthritis in 
common marmosets: A new nonhuman primate model for chronic arthritis. Arthritis 
Research and Therapy. 2010;12(5). doi:10.1186/ar3172 
76.  van den Berg WB, Joosten LAB, Helsen M, van de Loo FAJ. Amelioration of 
established murine collagen-induced arthritis with anti- IL-1 treatment. Clinical and 
Experimental Immunology. 1994;95(2):237-243. doi:10.1111/j.1365-
2249.1994.tb06517.x 
77.  Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of 
collagen-induced arthritis. Journal of Experimental Medicine. 1998;187(4):461-468. 
doi:10.1084/jem.187.4.461 
78.  Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint 
disease in murine collagen-induced arthritis. Proceedings of the National Academy of 




79.  Cremer MA, Ye XJ, Terato K, Owens SW, Seyer JM, Kang AH. Type XI collagen-
induced arthritis in the Lewis rat. Characterization of cellular and humoral immune 
responses to native types XI, V, and II collagen and constituent alpha-chains. The 
Journal of Immunology. 1994;153(2). 
80.  Tong D, Lönnblom E, Yau ACY, et al. A shared epitope of collagen type XI and type 
II is recognized by pathogenic antibodies in mice and humans with arthritis. Frontiers 
in Immunology. 2018;9(APR). doi:10.3389/fimmu.2018.00451 
81.  Carlsen S, Lu S, Holmdahl R. Arthritis induced with minor cartilage proteins. Methods 
in molecular medicine. 2007;136:225-242. doi:10.1007/978-1-59745-402-5_17 
82.  Lu S, Carlsen S, Hansson AS, Holmdahl R. Immunization of rats with homologous 
type XI collagen leads to chronic and relapsing arthritis with different genetics and 
joint pathology than arthritis induced with homologous type II collagen. Journal of 
Autoimmunity. 2002;18(3):199-211. doi:10.1006/jaut.2001.0581 
83.  Nandakumar KS, Svensson L, Holmdahl R. Collagen Type II-Specific Monoclonal 
Antibody-Induced Arthritis in Mice: Description of the Disease and the Influence of 
Age, Sex, and Genes. American Journal of Pathology. 2003;163(5):1827-1837. 
doi:10.1016/S0002-9440(10)63542-0 
84.  Viljanen J, Lönnblom E, Ge C, et al. Synthesis of an Array of Triple-Helical Peptides 
from Type II Collagen for Multiplex Analysis of Autoantibodies in Rheumatoid 
Arthritis. ACS Chemical Biology. 2020;15(9):2605-2615. 
doi:10.1021/acschembio.0c00680 
85.  Nandakumar KS, Bajtner E, Hill L, et al. Arthritogenic antibodies specific for a major 
type II collagen triple-helical epitope bind and destabilize cartilage independent of 
inflammation. Arthritis and Rheumatism. 2008;58(1):184-196. doi:10.1002/art.23049 
86.  Farinotti AB, Wigerblad G, Nascimento D, et al. Cartilage-binding antibodies induce 
pain through immune complex–mediated activation of neurons. Journal of 
Experimental Medicine. 2019;216(8):1904-1924. doi:10.1084/jem.20181657 
87.  Nandakumar KS, Holmdahl R. Efficient promotion of collagen antibody induced 
arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes 
recognized in both collagen induced arthritis and rheumatoid arthritis. Journal of 
Immunological Methods. 2005;304(1-2):126-136. doi:10.1016/j.jim.2005.06.017 
88.  Yau ACY, Lönnblom E, Zhong J, Holmdahl R. Influence of hydrocarbon oil structure 




89.  Tuncel J, Haag S, Hoffmann MH, et al. Animal models of rheumatoid arthritis (I): 
Pristane-induced arthritis in the rat. PLoS ONE. 2016;11(5). 
doi:10.1371/journal.pone.0155936 
90.  Olofsson P, Holmdahl R. Pristane-induced arthritis in the rat. Methods in molecular 
medicine. 2007;136:255-268. doi:10.1007/978-1-59745-402-5_19 
91.  Backdahl L, Aoun M, Norin U, Holmdahl R. Identification of Clec4b as a novel 
regulator of bystander activation of auto-reactive T cells and autoimmune disease. 
PLoS Genetics. 2020;16(6). doi:10.1371/journal.pgen.1008788 
92.  Yau ACY, Lönnblom E, Zhong J, Holmdahl R. Influence of hydrocarbon oil structure 
on adjuvanticity and autoimmunity. Scientific Reports. 2017;7(1). doi:10.1038/s41598-
017-15096-z 
93.  Tuncel J, Haag S, Carlsén S, et al. Class II major histocompatibility complex-
associated response to type XI collagen regulates the development of chronic arthritis 
in rats. Arthritis and Rheumatism. 2012;64(8):2537-2547. doi:10.1002/art.34461 
94.  Kleinau S, Klareskog L. Oil-induced arthritis in DA rats passive transfer by T cells but 
not with serum. Journal of Autoimmunity. 1993;6(4):449-458. 
doi:10.1006/jaut.1993.1037 
95.  Freitas EC, de Oliveira MS, Monticielo OA. Pristane-induced lupus: considerations on 
this experimental model. Clinical Rheumatology. 2017;36(11):2403-2414. 
doi:10.1007/s10067-017-3811-6 
96.  Geng H, Nandakumar KS, Pramhed A, Aspberg A, Mattsson R, Holmdahl R. 
Cartilage oligomeric matrix protein specific antibodies are pathogenic. Arthritis 
Research and Therapy. 2012;14(4). doi:10.1186/ar4022 
97.  Zhang Y, Guerassimov A, Leroux JY, et al. Arthritis induced by proteoglycan 
aggrecan G1 domain in BALB/c mice: Evidence for T cell involvement and the 
immunosuppressive influence of keratan sulfate on recognition of T and B cell 
epitopes. Journal of Clinical Investigation. 1998;101(8):1678-1686. 
doi:10.1172/JCI1666 
98.  Bockermann R, Schubert D, Kamradt T, Holmdahl R. Induction of a B-cell-dependent 
chronic arthritis with glucose-6-phosphate isomerase. Arthritis research & therapy. 
2005;7(6):1-9. doi:10.1186/ar1829 
99.  Maccioni M, Zeder-Lutz G, Huang H, et al. Arthritogenic monoclonal antibodies from 
K/BxN mice. Journal of Experimental Medicine. 2002;195(8):1071-1077. 
doi:10.1084/jem.20011941 
100.  Studelska DR, Mandik-Nayak L, Zhou X, et al. High affinity glycosaminoglycan and 
autoantigen interaction explains joint specificity in a mouse model of rheumatoid 
 
50 
arthritis. Journal of Biological Chemistry. 2009;284(4):2354-2362. 
doi:10.1074/jbc.M806458200 
101.  Christensen AD, Haase C, Cook AD, Hamilton JA. K/BxN serum-transfer arthritis as 
a model for human inflammatory arthritis. Frontiers in Immunology. 2016;7(JUN). 
doi:10.3389/fimmu.2016.00213 
102.  Kinloch AJ, Alzabin S, Brintnell W, et al. Immunization with porphyromonas 
gingivalis enolase induces autoimmunity to mammalian α-enolase and arthritis in 
DR4-IE-transgenic mice. Arthritis and Rheumatism. 2011;63(12):3818-3823. 
doi:10.1002/art.30639 
103.  Haag S, Uysal H, Bäcklund J, Tuncel J, Holmdahl R. Human α-enolase is 
immunogenic, but not arthritogenic, in HLA-DR4-transgenic mice: Comment on the 
article by Kinloch et al. Arthritis and Rheumatism. 2012;64(5):1689-1691. 
doi:10.1002/art.34379 
104.  Rose HM, Ragan C, Pearce E, Lipman MO. Differential Agglutination of Normal and 
Sensitized Sheep Erythrocytes by Sera of Patients with Rheumatoid Arthritis. 
Proceedings of the Society for Experimental Biology and Medicine. 1948;68(1):1-6. 
doi:10.3181/00379727-68-16375 
105.  Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: Clinical applications. 
Disease Markers. 2013;35(6):727-734. doi:10.1155/2013/726598 
106.  Newkirk MM. Rheumatoid factors: Host resistance or autoimmunity? Clinical 
Immunology. 2002;104(1):1-13. doi:10.1006/clim.2002.5210 
107.  Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: 
An American College of Rheumatology/European League Against Rheumatism 
collaborative initiative. Arthritis and Rheumatism. 2010;62(9):2569-2581. 
doi:10.1002/art.27584 
108.  Hecht C, Englbrecht M, Rech J, et al. Additive effect of anti-citrullinated protein 
antibodies and rheumatoid factor on bone erosions in patients with RA. Annals of the 
Rheumatic Diseases. 2015;74(12):2151-2156. doi:10.1136/annrheumdis-2014-205428 
109.  Sokolove J, Johnson DS, Lahey LJ, et al. Rheumatoid factor as a potentiator of anti-
citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis 
and Rheumatology. 2014;66(4):813-821. doi:10.1002/art.38307 
110.  NIENHUIS RL, MANDEMA E. A NEW SERUM FACTOR IN PATIENTS WITH 
RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR. Annals of the 
rheumatic diseases. 1964;23(4):302-305. doi:10.1136/ard.23.4.302 
 
 51 
111.  Young BJJ, Clark CJM, Hamblin TJ, Mallya RK, Leslie RDG. Anti-keratin antibodies 
in rheumatoid arthritis. British Medical Journal. 1979;2(6182):97-99. 
doi:10.1136/bmj.2.6182.97 
112.  Simon M, Girbal E, Sebbag M, et al. The cytokeratin filament-aggregating protein 
filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific 
for rheumatoid arthritis. Journal of Clinical Investigation. 1993;92(3):1387-1393. 
doi:10.1172/JCI116713 
113.  Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-called 
antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. 
Journal of Clinical Investigation. 1995;95(6):2672-2679. doi:10.1172/JCI117969 
114.  Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van 
Venrooij WJ. Citrulline is an essential constituent of antigenic determinants 
recognized by rheumatoid arthritis-specific autoantibodies. Journal of Clinical 
Investigation. 1998;101(1):273-281. doi:10.1172/JCI1316 
115.  de Rycke L, Peene I, Hoffman IEA, et al. Rheumatoid factor and anticitrullinated 
protein antibodies in rheumatoid arthritis: Diagnosis value, associations with 
radiological progression rate, and extra-articular manifestations. Annals of the 
Rheumatic Diseases. 2004;63(12):1587-1593. doi:10.1136/ard.2003.017574 
116.  Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental 
determinants for disease risk in subsets of rheumatoid arthritis defined by the 
anticitrullinated protein/peptide antibody fine specificity profile. Annals of the 
Rheumatic Diseases. 2013;72(5):652-658. doi:10.1136/annrheumdis-2012-201484 
117.  Hensvold AH, Magnusson PKE, Joshua V, et al. Environmental and genetic factors in 
the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive 
rheumatoid arthritis: An epidemiological investigation in twins. Annals of the 
Rheumatic Diseases. 2015;74(2):375-380. doi:10.1136/annrheumdis-2013-203947 
118.  Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI. How 
well do ACPA discriminate and predict RA in the general population: A study based 
on 12 590 population-representative Swedish twins. Annals of the Rheumatic Diseases. 
2017;76(1):119-125. doi:10.1136/annrheumdis-2015-208980 
119.  Carubbi F, Alunno A, Gerli R, Giacomelli R. Post-Translational Modifications of 
Proteins: Novel Insights in the Autoimmune Response in Rheumatoid Arthritis. Cells. 
2019;8(7):657. doi:10.3390/cells8070657 
120.  Kissel T, Reijm S, Slot LM, et al. Antibodies and B cells recognising citrullinated 
proteins display a broad cross-reactivity towards other post-translational modifications. 




121.  Reed E, Jiang X, Kharlamova N, et al. Antibodies to carbamylated α-enolase epitopes 
in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from 
anti-citrullinated protein antibodies. Arthritis Research and Therapy. 2016;18(1). 
doi:10.1186/s13075-016-1001-6 
122.  Steffen C. Consideration of pathogenesis of rheumatoid arthritis as collagen 
autoimmunity. Zeitschrift fur Immunitatsforschung, Allergie und klinische 
Immunologie. 1970;139(3):219-227. Accessed May 8, 2021. https://pubmed-ncbi-nlm-
nih-gov.proxy.kib.ki.se/4250050/ 
123.  Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: An 
experimental model of arthritis*. Journal of Experimental Medicine. 1977;146(3):857-
868. doi:10.1084/jem.146.3.857 
124.  Holmdahl R, Rubin K, Klareskog L, Larsson E, Wigzell H. Characterization of the 
antibody response in mice with type II collagen–induced arthritis, using monoclonal 
anti–type II collagen antibodies. Arthritis & Rheumatism. 1986;29(3):400-410. 
doi:10.1002/art.1780290314 
125.  Nandakumar KS, Holmdahl R. Collagen antibody induced arthritis. Methods in 
molecular medicine. 2007;136:215-223. doi:10.1007/978-1-59745-402-5_16 
126.  Manivel VA, Mullazehi M, Padyukov L, et al. Anticollagen type II antibodies are 
associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower 
degree of inflammation during 5 years follow-up. Annals of the rheumatic diseases. 
2017;76(9):1529-1536. doi:10.1136/annrheumdis-2016-210873 
127.  Mullazehi M, Wick MC, Klareskog L, van Vollenhoven R, Rönnelid J. Anti-type II 
collagen antibodies are associated with early radiographic destruction in rheumatoid 
arthritis. Arthritis Research and Therapy. 2012;14(3). doi:10.1186/ar3825 
128.  Manivel VA, van der Woude D, Toes R, Filer A, Raza K, Rönnelid J. Antibodies 
against collagen type II are not a general marker of acute arthritis onset. Annals of the 
Rheumatic Diseases. 2018;77(6):954-955. doi:10.1136/annrheumdis-2017-211974 
129.  Cook AD, Gray R, Ramshaw J, Mackay IR, Rowley MJ. Antibodies against the CB10 
fragment of type II collagen in rheumatoid arthritis. Arthritis research & therapy. 
2004;6(5). doi:10.1186/ar1213 
130.  Beard HK, Ryvar R, Skingle J, Greenburyt CL. Anti-collagen antibodies in sera from 
rheumatoid arthritis patients. Journal of Clinical Pathology. 1980;33(11):1077-1081. 
doi:10.1136/jcp.33.11.1077 
131.  Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid 
arthritis in subjects with anticitrullinated protein antibodies. Annals of the Rheumatic 
Diseases. 2014;73(5):854-860. doi:10.1136/annrheumdis-2012-202958 
 
 53 
132.  van Heemst J, Trouw LA, Nogueira L, et al. An investigation of the added value of an 
ACPA multiplex assay in an early rheumatoid arthritis setting. Arthritis Research and 
Therapy. 2015;17(1). doi:10.1186/s13075-015-0786-z 
133.  Boman A, Brink M, Lundquist A, et al. Antibodies against citrullinated peptides are 
associated with clinical and radiological outcomes in patients with early rheumatoid 
arthritis: a prospective longitudinal inception cohort study. RMD open. 
2019;5(2):e000946. doi:10.1136/rmdopen-2019-000946 
134.  Kastbom A, Forslind K, Ernestam S, et al. Changes in the anticitrullinated peptide 
antibody response in relation to therapeutic outcome in early rheumatoid arthritis: 
Results from the SWEFOT trial. Annals of the Rheumatic Diseases. 2016;75(2):356-
361. doi:10.1136/annrheumdis-2014-205698 
135.  Jonsson MK, Hensvold AH, Hansson M, et al. The role of anti-citrullinated protein 
antibody reactivities in an inception cohort of patients with rheumatoid arthritis 
receiving treat-to-target therapy. Arthritis Research and Therapy. 2018;20(1). 
doi:10.1186/s13075-018-1635-7 
136.  Shoda H, Fujio K, Shibuya M, et al. Detection of autoantibodies to citrullinated BiP in 
rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in 
collagen-induced arthritis. Arthritis Research and Therapy. 2011;13(6). 
doi:10.1186/ar3520 
137.  Sandal I, Karydis A, Luo J, et al. Bone loss and aggravated autoimmune arthritis in 
HLA-DRβ1-bearing humanized mice following oral challenge with Porphyromonas 
gingivalis. Arthritis Research and Therapy. 2016;18(1). doi:10.1186/s13075-016-
1143-6 
138.  Thiele GM, Duryee MJ, Dusad A, et al. Citrullinated mouse collagen administered to 
DBA/1J mice in the absence of adjuvant initiates arthritis. International 
Immunopharmacology. 2012;13(4):424-431. doi:10.1016/j.intimp.2012.05.007 
139.  Yamada H, Ozawa T, Kishi H, et al. Cutting Edge: B Cells Expressing Cyclic 
Citrullinated Peptide–Specific Antigen Receptor Are Tolerized in Normal Conditions. 
The Journal of Immunology. 2018;201(12):3492-3496. 
doi:10.4049/jimmunol.1800826 
140.  Titcombe PJ, Wigerblad G, Sippl N, et al. Pathogenic Citrulline-Multispecific B Cell 
Receptor Clades in Rheumatoid Arthritis. Arthritis and Rheumatology. 
2018;70(12):1933-1945. doi:10.1002/art.40590 
141.  Krishnamurthy A, Joshua V, Hensvold AH, et al. Identification of a novel chemokine-
dependent molecular mechanism underlying Rheumatoid arthritisassociated 




142.  Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by 
human autoantibodies against citrullinated vimentin. Journal of Clinical Investigation. 
2012;122(5):1791-1802. doi:10.1172/JCI60975 
143.  Uysal H, Bockermann R, Nandakumar KS, et al. Structure and pathogenicity of 
antibodies specific for citrullinated collagen type II in experimental arthritis. Journal 
of Experimental Medicine. 2009;206(2):449-462. doi:10.1084/jem.20081862 
144.  Ge C, Tong D, Liang B, et al. Anti-citrullinated protein antibodies cause arthritis by 
cross-reactivity to joint cartilage. Journal of Clinical Investigation. 2017;2(13). 
doi:10.1172/jci.insight.93688 
145.  Ge C, Xu B, Liang B, et al. Structural Basis of Cross-Reactivity of Anti–Citrullinated 
Protein Antibodies. Arthritis and Rheumatology. 2019;71(2):210-221. 
doi:10.1002/art.40698 
146.  Ge C, Holmdahl R. The structure, specificity and function of anti-citrullinated protein 
antibodies. Nature Reviews Rheumatology. 2019;15(8):503-508. doi:10.1038/s41584-
019-0244-4 
147.  Holmdahl R, Malmström V, Burkhardt H. Autoimmune priming, tissue attack and 
chronic inflammation - The three stages of rheumatoid arthritis. European Journal of 
Immunology. 2014;44(6):1593-1599. doi:10.1002/eji.201444486 
148.  Holers VM, Demoruelle MK, Kuhn KA, et al. Rheumatoid arthritis and the mucosal 
origins hypothesis: protection turns to destruction. Nature Reviews Rheumatology. 
2018;14(9):542-557. doi:10.1038/s41584-018-0070-0 
149.  Kelmenson LB, Wagner BD, McNair BK, et al. Timing of Elevations of Autoantibody 
Isotypes Prior to Diagnosis of Rheumatoid Arthritis. Arthritis and Rheumatology. 
2020;72(2):251-261. doi:10.1002/art.41091 
150.  Courvoisier DS, Chatzidionysiou K, Mongin D, et al. The impact of seropositivity on 
the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 
registries. Rheumatology. 2021;60(2):820-828. doi:10.1093/rheumatology/keaa393 
151.  Lu S, Carlsen S, Hansson AS, Holmdahl R. Immunization of rats with homologous 
type XI collagen leads to chronic and relapsing arthritis with different genetics and 
joint pathology than arthritis induced with homologous type II collagen. Journal of 
Autoimmunity. 2002;18(3):199-211. doi:10.1006/jaut.2001.0581 
152.  Tong D, Lönnblom E, Yau ACY, et al. A Shared Epitope of Collagen Type XI and 
Type II Is Recognized by Pathogenic Antibodies in Mice and Humans with Arthritis. 
Frontiers in immunology. 2018;9(APR):451. doi:10.3389/fimmu.2018.00451 
 
 55 
153.  Andersson MLE, Forslind K, Hafström I. Comparing Five Year Out-Come in Two 
Cohorts of Patients with Early Rheumatoid Arthritis – A BARFOT Study. The Open 
Rheumatology Journal. 2015;9(1):8-15. doi:10.2174/1874312901409010008 
154.  Arnett FC, Edworthy SM, Bloch DA, et al. The american rheumatism association 1987 
revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism. 
1988;31(3):315-324. doi:10.1002/art.1780310302 
155.  Kats A, Båge T, Georgsson P, et al. Inhibition of microsomal prostaglandin e 
synthase-1 by aminothiazoles decreases prostaglandin E2 synthesis in vitro and 
ameliorates experimental periodontitis in vivo. FASEB Journal. 2013;27(6):2328-
2341. doi:10.1096/fj.12-214445 
156.  Tuncel J, Haag S, Hoffmann MH, et al. Animal models of rheumatoid arthritis (I): 
Pristane-induced arthritis in the rat. PLoS ONE. 2016;11(5). 
doi:10.1371/journal.pone.0155936 
157.  Lundberg K, Kinloch A, Fisher BA, et al. Antibodies to citrullinated α-enolase peptide 
1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis 
and Rheumatism. 2008;58(10):3009-3019. doi:10.1002/art.23936 
158.  Kharlamova N, Jiang X, Sherina N, et al. Antibodies to Porphyromonas gingivalis 
Indicate Interaction between Oral Infection, Smoking, and Risk Genes in Rheumatoid 
Arthritis Etiology. Arthritis and Rheumatology. 2016;68(3):604-613. 
doi:10.1002/art.39491 
159.  Mikuls TR, Thiele GM, Deane KD, et al. Porphyromonas gingivalis and disease-
related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis 
and Rheumatism. 2012;64(11):3522-3530. doi:10.1002/art.34595 
160.  Bartold PM, Marino V, Cantley M, Haynes DR. Effect of Porphyromonas gingivalis-
induced inflammation on the development of rheumatoid arthritis. Journal of Clinical 
Periodontology. 2010;37(5):405-411. doi:10.1111/j.1600-051X.2010.01552.x 
161.  Marchesan JT, Gerow EA, Schaff R, et al. Porphyromonas gingivalis oral infection 
exacerbates the development and severity of collagen-induced arthritis. Arthritis 
Research and Therapy. 2013;15(6). doi:10.1186/ar4376 
162.  Bradshaw DJ, Marsh PD, Keith Watson G, Allison C. Role of Fusobacterium 
nucleatum and coaggregation in anaerobe survival in planktonic and biofilm oral 
microbial communities during aeration. Infection and Immunity. 1998;66(10):4729-
4732. doi:10.1128/iai.66.10.4729-4732.1998 
163.  Polak D, Wilensky A, Shapira L, et al. Mouse model of experimental periodontitis 
induced by Porphyromonas gingivalisFusobacterium nucleatum infection: Bone loss 
 
56 
and host response. Journal of Clinical Periodontology. 2009;36(5):406-410. 
doi:10.1111/j.1600-051X.2009.01393.x 
164.  Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice. Journal of 
Experimental Medicine. 1983;158(2):378-392. doi:10.1084/jem.158.2.378 
165.  Fischer A, Abdollahi-Roodsaz S, Böhm C, et al. The involvement of Toll-like receptor 
9 in the pathogenesis of erosive autoimmune arthritis. Journal of Cellular and 
Molecular Medicine. 2018;22(9):4399-4409. doi:10.1111/jcmm.13735 
166.  Maresz KJ, Hellvard A, Sroka A, et al. Porphyromonas gingivalis Facilitates the 
Development and Progression of Destructive Arthritis through Its Unique Bacterial 
Peptidylarginine Deiminase (PAD). PLoS Pathogens. 2013;9(9):e1003627. 
doi:10.1371/journal.ppat.1003627 
167.  Johansson L, Sherina N, Kharlamova N, et al. Concentration of antibodies against 
Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid 
arthritis. Arthritis Research and Therapy. 2016;18(1):1-10. doi:10.1186/s13075-016-
1100-4 
168.  Fisher BA, Cartwright AJ, Quirke AM, et al. Smoking, Porphyromonas gingivalis and 
the immune response to citrullinated autoantigens before the clinical onset of 
rheumatoid arthritis in a Southern European nested case-control study Clinical 
rheumatology and osteoporosis. BMC Musculoskeletal Disorders. 2015;16(1):1-11. 
doi:10.1186/s12891-015-0792-y 
169.  Konig MF, Paracha AS, Moni M, Bingham CO, Andrade F. Defining the role of 
Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis 
through the study of PPAD biology. Annals of the Rheumatic Diseases. 
2015;74(11):2054-2061. doi:10.1136/annrheumdis-2014-205385 
170.  Quirke AM, Lundberg K, Potempa J, Mikuls TR, Venables PJ. PPAD remains a 
credible candidate for inducing autoimmunity in rheumatoid arthritis: Comment on the 
article by Konig et al. Annals of the Rheumatic Diseases. 2015;74(1):e7. 
doi:10.1136/annrheumdis-2014-206665 
171.  Rowley MJ, Selva Nandakumar K, Holmdahl R, Rowley AE Kutty Selva Nandakumar 
AE Rikard Holmdahl MJ. The role of collagen antibodies in mediating arthritis. 
Modern Rheumatology. 2008;18(5):429-441. doi:10.3109/s10165-008-0080-x 
172.  Nandakumar KS, Bajtner E, Hill L, et al. Arthritogenic antibodies specific for a major 
type II collagen triple-helical epitope bind and destabilize cartilage independent of 
inflammation. Arthritis and Rheumatism. 2008;58(1):184-196. doi:10.1002/art.23049 
173.  Burkhardt H, Koller T, Engström Å, et al. Epitope-specific recognition of type II 
collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies 
 
 57 
that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis and 
Rheumatism. 2002;46(9):2339-2348. doi:10.1002/art.10472 
174.  Dobritzsch D, Lindh I, Uysal H, et al. Crystal structure of an arthritogenic anticollagen 
immune complex. Arthritis and Rheumatism. 2011;63(12):3740-3748. 
doi:10.1002/art.30611 
175.  Fields CG, Lovdahl CM, Miles AJ, Hageini VLM, Fields GB. Solid‐Phase synthesis 
and stability of triple‐helical peptides incorporating native collagen sequences. 
Biopolymers. 1993;33(11):1695-1707. doi:10.1002/bip.360331107 
176.  Frank S, Kammerer RA, Mechling D, et al. Stabilization of short collagen-like triple 
helices by protein engineering. Journal of Molecular Biology. 2001;308(5):1081-1089. 
doi:10.1006/jmbi.2001.4644 
177.  Persikov A v., Ramshaw JAM, Brodsky B. Prediction of collagen stability from amino 
acid sequence. Journal of Biological Chemistry. 2005;280(19):19343-19349. 
doi:10.1074/jbc.M501657200 
178.  Haag S, Schneider N, Mason DE, et al. Identification of new citrulline-specific 
autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis 
of citrullinated type ii collagen. Arthritis and Rheumatology. 2014;66(6):1440-1449. 
doi:10.1002/art.38383 
179.  Croxford AM, Crombie D, McNaughton D, Holmdahl R, Nandakumar KS, Rowley 
MJ. Specific antibody protection of the extracellular cartilage matrix against collagen 
antibody-induced damage. Arthritis and Rheumatism. 2010;62(11):3374-3384. 
doi:10.1002/art.27671 
180.  Eyre DR, Weis MA, Wu JJ. Advances in collagen cross-link analysis. Methods. 
2008;45(1):65-74. doi:10.1016/j.ymeth.2008.01.002 
181.  Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Periodontitis in RA-the 
citrullinated enolase connection. Nature Reviews Rheumatology. 2010;6(12):727-730. 
doi:10.1038/nrrheum.2010.139 
182.  Ioan-Facsinay A, El-Bannoudi H, Scherer HU, et al. Anti-cyclic citrullinated peptide 
antibodies are a collection of anti-citrullinated protein antibodies and contain 
overlapping and non-overlapping reactivities. Annals of the Rheumatic Diseases. 
2011;70(1):188-193. doi:10.1136/ard.2010.131102 
183.  Trouw LA, Rispens T, Toes REM. Beyond citrullination: Other post-translational 




184.  Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. 
Genetic and environmental risk factors for rheumatoid arthritis. Best Practice and 
Research: Clinical Rheumatology. 2017;31(1):3-18. doi:10.1016/j.berh.2017.08.003 
185.  Stanich JA, Carter JD, Whittum-Hudson J, Hudson AP. Rheumatoid arthritis: Disease 
or syndrome? Open Access Rheumatology: Research and Reviews. 2009;1(1):179-192. 
doi:10.2147/oarrr.s7680 
186.  Xing Y, Wang S, Liu C, et al. Efficacy and safety of dual filtration plasmapheresis 
combined with biological agents in active refractory rheumatod arthritis: A 
retrospective cohort study. Medicine. 2020;99(28):e20966. 
doi:10.1097/MD.0000000000020966 
187.  Nandakumar KS, Collin M, Happonen KE, et al. Streptococcal Endo-β-N-
acetylglucosaminidase suppresses antibody-mediated inflammation in vivo. Frontiers 
in Immunology. 2018;9(JUL). doi:10.3389/fimmu.2018.01623 
188.  Washburn N, Schwabb I, Ortiz D, et al. Controlled tetra-Fc sialylation of IVIg results 
in a drug candidate with consistent enhanced anti-inflammatory activity. Proceedings 
of the National Academy of Sciences of the United States of America. 
2015;112(11):E1297-E1306. doi:10.1073/pnas.1422481112 
189.  Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-Cell–Targeted 
Therapy with Rituximab in Patients with Rheumatoid Arthritis. New England Journal 
of Medicine. 2004;350(25):2572-2581. doi:10.1056/nejmoa032534 
  
